α6β2* and α4β2* Nicotinic Acetylcholine Receptors As Drug Targets for Parkinson's Disease

Maryka Quik and Susan Wonnacott

Center for Health Sciences, SRI International, Menlo Park, California (M.Q.); and Department of Biology and Biochemistry, University of Bath, Bath, United Kingdom (S.W.)

Abstract

Parkinson's disease is a debilitating movement disorder characterized by a generalized dysfunction of the nervous system, with a particularly prominent decline in the nigrostriatal dopaminergic pathway. Although there is currently no cure, drugs targeting the dopaminergic system provide major symptomatic relief. As well, agents directed to other neurotransmitter systems are of therapeutic benefit. Such drugs may act by directly improving functional deficits...
I. Introduction—Parkinson’s Disease and Links to the Nicotinic Cholinergic System

Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease, and affects 2% of people over the age of 60 (Mayeux, 2003). It is a neurodegenerative movement disorder characterized by postural instability, bradykinesia and a generally asymmetric onset of tremor and rigidity (Lang, 2009; Poewe, 2009; Quik et al., 2009; Schapira, 2009; Feng and Maguire-Zeiss, 2010; Obeso et al., 2010). These motor symptoms are a consequence of degeneration of the nigrostriatal dopaminergic pathway, which is the most severely affected neurotransmitter system in Parkinson’s disease. In addition, accumulating evidence shows that there is a generalized neuronal loss in the central and peripheral nervous system in this disorder (Braak et al., 2002, 2003). Numerous CNS1 neurotransmitter systems degenerate, such as the adrenergic, cholinergic, serotonergic, glutamatergic, and GABAergic pathways, although to a lesser degree than the nigrostriatal dopaminergic pathway (Curzon, 1977; Haber, 1986; Dubois et al., 1990; Poewe, 2009). Damage to these other systems may contribute to the motor problems and also underlie the nonmotor symptoms associated with Parkinson’s disease, including deficits in cognition/memory, affect, sleep/wakefulness, and autonomic function (Lang, 2009; Poewe, 2009; Quik et al., 2009; Schapira, 2009; Calabresi et al., 2010; Feng and Maguire-Zeiss, 2010; Obeso et al., 2010).

The etiology of Parkinson’s disease is currently uncertain and has been attributed to a complex interplay between genetic and environmental factors (Schapira, 2009; Bekris et al., 2010; Obeso et al., 2010). A small minority of cases (~5%) is genetic (familial), with Mendelian inheritance. Gene mutations linked to Parkinson’s disease include PARK1 to PARK18, which seem to be responsible for approximately 50% of familial cases and ~2% of sporadic forms (Schapira, 2009; Obeso et al., 2010). Of these, the most well studied include PARK1/4, which involves point mutations and multiplications in the α-synuclein gene. Deletions or point mutations in the PARK2 gene, which encodes parkin, are linked to autosomal recessive juvenile-onset parkinsonism. Recessive mutations in PARK6 or PINK1 (which encodes a mitochondrial recessive kinase) are responsible for a familial form of early-onset parkinsonism. Recessively inherited missense and exonic deletion mutations in PARK7 or DJ1 have also been reported although these are very rare. The most common mutations in either familial or sporadic Parkinson’s disease involve mutations in PARK8 or LRRK2 (encoding leucine-rich repeat kinase 2). The LRRK2 protein contains both Rab GTPase and kinase enzymatic activities, which have been implicated in multiple neuronal functions under physiological conditions. In addition to genetic mutations, environmental factors have also been linked to the occurrence of Parkinson’s disease. The greatest positive risk factor is pesticide exposure, whereas tobacco use has consistently been linked to a decreased incidence of Parkinson’s disease (Quik et al., 2009).

The most effective current treatment for Parkinson’s disease motor symptoms is dopamine replacement therapy with l-DOPA and/or dopamine agonists. These drugs are particularly beneficial for improving motor deficits in Parkinson’s disease; however, side effects commonly arise and drug effectiveness diminishes with disease progression (Lang, 2009; Poewe, 2009; Quik et al., 2009; Schapira, 2009; Feng and Maguire-Zeiss, 2010; Obeso et al., 2010). Moreover, the nonmotor symptoms linked to Parkinson’s disease, such as dementia, sleep deficits, depression, and others, are not improved with these pharmacotherapies. There is therefore a critical need to develop improved treatments for Parkinson’s disease, ideally to halt disease progression but also to provide better symptomatic relief of the motor and nonmotor symptoms. The focus of this review is on a potential role for the nicotinic cholinergic system, based on the following rationale: a considerable literature demonstrates an extensive anatomical and functional overlap between the nicotinic cholinergic and dopaminergic systems, or they may restore aberrant motor activity that arises as a result of a dopaminergic imbalance. Recent research attention has focused on a role for drugs targeting the nicotinic cholinergic system. The rationale for such work stems from basic research findings that there is an extensive overlap in the organization and function of the nicotinic cholinergic and dopaminergic systems in the basal ganglia. In addition, nicotinic acetylcholine receptor (nAChR) drugs could have clinical potential for Parkinson’s disease. Evidence for this proposition stems from studies with experimental animal models showing that nicotine protects against neurotoxin-induced nigrostriatal damage and improves motor complications associated with l-DOPA, the “gold standard” for Parkinson’s disease treatment. Nicotine interacts with multiple central nervous system receptors to generate therapeutic responses but also produces side effects. It is important therefore to identify the nAChR subtypes most beneficial for treating Parkinson’s disease. Here we review nAChRs with particular emphasis on the subtypes that contribute to basal ganglia function. Accumulating evidence suggests that drugs targeting α6β2* and α4β2* nAChR may prove useful in the management of Parkinson’s disease.
minergic systems in the nigrostriatal pathway, which plays a pivotal role in Parkinson’s disease. In addition, accumulating studies suggest that drugs that interact at nAChRs, such as nicotine, may protect against nigrostriatal damage. Moreover, nicotine and nAChR drugs alleviate some of the motor side effects associated with dopamine replacement therapy. Finally, the emerging procognitive and antidepressant effects of nAChR drugs may offer therapeutic benefit for the dementia and depressive symptoms observed in Parkinson’s disease.

II. Inter-Relationship between Nicotinic Cholinergic and Dopaminergic Systems

A. Striatum

The subcortical region, referred to as the striatum because of its striated or striped appearance, consists of the caudate nucleus and putamen. In rodents, the caudate and the putamen are merged, but in primates, these structures are separated by the internal capsule. The striatum is divided into dorsal and ventral territories. The dorsal striatum primarily receives dopaminergic innervation from the substantia nigra (SN) pars compacta, with little contribution from the ventral tegmental area (VTA) (Björklund and Dunnett, 2007) (Fig. 1). It is this nigrostriatal pathway that selectively degenerates in Parkinson’s disease (Fig. 1) (Obeso et al., 2000; Parent et al., 2000; Smith and Kieval, 2000). Dopaminergic innervation of the ventral striatum (also known as the nucleus accumbens core) is from the VTA, with some input from the dorsal SN. Likewise, primate dorsal striatum primarily receives projections from the SN. However, there is a more pronounced “intermingling” of the pathways from the SN and VTA in the ventral striatum or nucleus accumbens in primates (Björklund and Dunnett, 2007). In Parkinson’s disease, the dorsal striatum is affected to the greatest degree, reflecting the degeneration of the nigrostriatal pathway, whereas the mesolimbic projection from the VTA is relatively spared (Obeso et al., 2000; Parent et al., 2000; Smith and Kieval, 2000). Unless specified, the term “striatum” will henceforth be used to denote the striatal areas compromised in Parkinson’s disease.

The striatum boasts some of the highest levels of dopamine and acetylcholine (ACh) in the brain (Fig. 2). Historically these two transmitters were viewed as having antagonistic roles (Calabresi et al., 2000; Cragg, 2006), reflecting the beneficial effects of muscarinic antagonists in Parkinson’s disease (Langmead et al., 2008). The terminal fields of the dopaminergic afferents have extensive arborizations (Wilson and Groves, 1980). Thus, each dopaminergic afferent contacts a large area of the striatum to exert a coordinated influence (Fig. 2). The principal target is the GABAergic medium spiny projection neurons, which constitute more than 90% of the neuronal population in the striatum. These neurons form the direct and indirect output pathways to the basal ganglia whereby motor function is moderated (Bolam et al., 2000; Obeso et al., 2000; Parent et al., 2000; Smith and Kieval, 2000). In the direct pathway, information from the striatum is transmitted directly to the output structures of the basal ganglia. These include the SN pars reticulata and the entopeduncular nucleus in rodents (the latter corresponds to the internal segment of globus pallidus in primates), and thence to the brainstem (for the control of head, neck, and eye movements involved in gaze and focus) or the thalamus and motor cortex, respectively (Fig. 3). The indirect pathway proceeds via the globus pallidus (the external segment of globus pallidus in primates) and subthalamic nucleus before reaching the SN pars reticulata and the entopeduncular nucleus. The dopaminergic input to the striatum from the SN represents a substantial feedback component of this circuitry (Bolam et al., 2000).
The dopamine axons form symmetric synapses onto the shafts of the dendritic spines of medium spiny neurons. Here they are well placed to modulate the incoming activity from corticostriatal glutamatergic afferents that form asymmetric synapses onto the heads of the spines (Smith and Bolam, 1990) (see Fig. 4a). There is evidence for cholinergic synapses on distal dendrites and dendritic spines within the striatum, but ACh is also released nonsynaptically from varicosities to exert effects by volume transmission (Descarries et al., 1997). The cholinergic interneurons are tonically active, firing action potentials at a regular, slow rate (3–10/s) that results in a continuous pulsatile release of ACh under basal conditions (Wilson et al., 1990). The high levels of acetylcholinesterase present in the striatum facilitate the rapid hydrolysis of ACh, enabling extracellular ACh to reflect its pulsatile release, thus minimizing receptor desensitization (Zhou et al., 2001). This contrasts with the concentration profile achieved by exogenous drugs such as nicotine.

The dopamine afferents also exhibit a tonic activity at rest (the regular firing of single action potentials that constitutes a rhythmic pacemaker function). This results in a continuous “drip feed” of dopamine that maintains a tonic concentration of 10 to 20 nM in the striatum (Goto et al., 2007). Thus, spillover of dopamine and ACh released under resting conditions facilitates their interaction. Activations half a million varicosities within a territory of up to 1 mm in diameter (Zhou et al., 2002; Tepper and Bolam, 2004). Thus throughout the striatum there is extensive overlap with the dopaminergic arborization that facilitates their cross-talk (Fig. 2). There is evidence for cholinergic synapses on distal dendrites and dendritic spines within the striatum, but ACh is also released nonsynaptically from varicosities to exert effects by volume transmission (Descarries et al., 1997). The cholinergic interneurons are tonically active, firing action potentials at a regular, slow rate (3–10/s) that results in a continuous pulsatile release of ACh under basal conditions (Wilson et al., 1990). The high levels of acetylcholinesterase present in the striatum facilitate the rapid hydrolysis of ACh, enabling extracellular ACh to reflect its pulsatile release, thus minimizing receptor desensitization (Zhou et al., 2001). This contrasts with the concentration profile achieved by exogenous drugs such as nicotine.

The dopamine afferents also exhibit a tonic activity at rest (the regular firing of single action potentials that constitutes a rhythmic pacemaker function). This results in a continuous “drip feed” of dopamine that maintains a tonic concentration of 10 to 20 nM in the striatum (Goto et al., 2007). Thus, spillover of dopamine and ACh released under resting conditions facilitates their interaction. Activations half a million varicosities within a territory of up to 1 mm in diameter (Zhou et al., 2002; Tepper and Bolam, 2004). Thus throughout the striatum there is extensive overlap with the dopaminergic arborization that facilitates their cross-talk (Fig. 2). There is evidence for cholinergic synapses on distal dendrites and dendritic spines within the striatum, but ACh is also released nonsynaptically from varicosities to exert effects by volume transmission (Descarries et al., 1997). The cholinergic interneurons are tonically active, firing action potentials at a regular, slow rate (3–10/s) that results in a continuous pulsatile release of ACh under basal conditions (Wilson et al., 1990). The high levels of acetylcholinesterase present in the striatum facilitate the rapid hydrolysis of ACh, enabling extracellular ACh to reflect its pulsatile release, thus minimizing receptor desensitization (Zhou et al., 2001). This contrasts with the concentration profile achieved by exogenous drugs such as nicotine.

The dopamine afferents also exhibit a tonic activity at rest (the regular firing of single action potentials that constitutes a rhythmic pacemaker function). This results in a continuous “drip feed” of dopamine that maintains a tonic concentration of 10 to 20 nM in the striatum (Goto et al., 2007). Thus, spillover of dopamine and ACh released under resting conditions facilitates their interaction. Activations half a million varicosities within a territory of up to 1 mm in diameter (Zhou et al., 2002; Tepper and Bolam, 2004). Thus throughout the striatum there is extensive overlap with the dopaminergic arborization that facilitates their cross-talk (Fig. 2). There is evidence for cholinergic synapses on distal dendrites and dendritic spines within the striatum, but ACh is also released nonsynaptically from varicosities to exert effects by volume transmission (Descarries et al., 1997). The cholinergic interneurons are tonically active, firing action potentials at a regular, slow rate (3–10/s) that results in a continuous pulsatile release of ACh under basal conditions (Wilson et al., 1990). The high levels of acetylcholinesterase present in the striatum facilitate the rapid hydrolysis of ACh, enabling extracellular ACh to reflect its pulsatile release, thus minimizing receptor desensitization (Zhou et al., 2001). This contrasts with the concentration profile achieved by exogenous drugs such as nicotine.

The dopamine afferents also exhibit a tonic activity at rest (the regular firing of single action potentials that constitutes a rhythmic pacemaker function). This results in a continuous “drip feed” of dopamine that maintains a tonic concentration of 10 to 20 nM in the striatum (Goto et al., 2007). Thus, spillover of dopamine and ACh released under resting conditions facilitates their interaction. Activations half a million varicosities within a territory of up to 1 mm in diameter (Zhou et al., 2002; Tepper and Bolam, 2004). Thus throughout the striatum there is extensive overlap with the dopaminergic arborization that facilitates their cross-talk (Fig. 2). There is evidence for cholinergic synapses on distal dendrites and dendritic spines within the striatum, but ACh is also released nonsynaptically from varicosities to exert effects by volume transmission (Descarries et al., 1997). The cholinergic interneurons are tonically active, firing action potentials at a regular, slow rate (3–10/s) that results in a continuous pulsatile release of ACh under basal conditions (Wilson et al., 1990). The high levels of acetylcholinesterase present in the striatum facilitate the rapid hydrolysis of ACh, enabling extracellular ACh to reflect its pulsatile release, thus minimizing receptor desensitization (Zhou et al., 2001). This contrasts with the concentration profile achieved by exogenous drugs such as nicotine.

The dopamine afferents also exhibit a tonic activity at rest (the regular firing of single action potentials that constitutes a rhythmic pacemaker function). This results in a continuous “drip feed” of dopamine that maintains a tonic concentration of 10 to 20 nM in the striatum (Goto et al., 2007). Thus, spillover of dopamine and ACh released under resting conditions facilitates their interaction. Activations half a million varicosities within a territory of up to 1 mm in diameter (Zhou et al., 2002; Tepper and Bolam, 2004). Thus throughout the striatum there is extensive overlap with the dopaminergic arborization that facilitates their cross-talk (Fig. 2). There is evidence for cholinergic synapses on distal dendrites and dendritic spines within the striatum, but ACh is also released nonsynaptically from varicosities to exert effects by volume transmission (Descarries et al., 1997). The cholinergic interneurons are tonically active, firing action potentials at a regular, slow rate (3–10/s) that results in a continuous pulsatile release of ACh under basal conditions (Wilson et al., 1990). The high levels of acetylcholinesterase present in the striatum facilitate the rapid hydrolysis of ACh, enabling extracellular ACh to reflect its pulsatile release, thus minimizing receptor desensitization (Zhou et al., 2001). This contrasts with the concentration profile achieved by exogenous drugs such as nicotine.
tion of midbrain dopamine neurons switches their activity to a “bursting” firing pattern, a phasic pattern of bursts of action potentials (Grace et al., 2007). The consequence is substantially greater dopamine release in the striatum, transiently achieving high micromolar or even millimolar levels (Goto et al., 2007). Burst firing of dopamine neurons

FIG. 4. Cellular localization of nAChR subtypes in striatum (a) and SN (b). a. In the striatum, the nigrostriatal and corticostriatal afferents converge on the shafts and heads, respectively, of the spines of medium spiny projection neurons. The nigrostriatal dopaminergic terminals (DA) bear a variety of α4β2* and α6β2* nAChR subtypes. α7 nAChRs are proposed to reside on the glutamatergic terminals (Glu). Other neuronal elements in the striatum, the GABAergic and cholinergic interneurons and serotonergic afferents from the raphe nucleus, are also indicated. GABAergic terminals express α4β2* nAChRs: these may arise from interneurons, as illustrated, or from axon collaterals, medium spiny neurons, or globus pallidus neurons (not shown). A fast-spiking subpopulation of GABAergic interneurons may express an unidentified subtype of nAChR, possibly α7 (gray receptor). Evidence for the presence of nAChRs on cholinergic interneurons and serotonergic afferents is inconclusive (gray receptor). The subunit composition of nAChR subtypes expressed in the striatum is illustrated in the right panel. Two agonist-binding sites are indicated at the interface between α and β2 subunits in heteromeric nAChRs, whereas α7 nAChRs have five putative binding sites, as illustrated on the right. α7 nAChRs are also present on a proportion of these cell bodies, in contrast to the striatal dopaminergic terminals. GABAergic interneurons express heteromeric nAChRs; α4β2* nAChRs may also be present on GABAergic afferents, for example from the substantia nigra pars reticulata. In contrast to the VTA, glutamatergic afferents may bear both α7 and non-α7 nAChRs, but cholinergic afferents are apparently devoid of nAChRs.
is accompanied by silencing of the cholinergic interneurons, so ACh release ceases when dopamine release increases. This coordinated reciprocal response, which relies on both nigrostriatal and thalamic inputs to the striatum, emphasizes the complex interrelationship between dopamine and cholinergic systems in this region (Zhou et al., 2002; Cragg, 2006). The dopamine terminals have a rich array of nAChR subtypes, whereas there is no consistent evidence for nicotinic autoreceptors on the cholinergic interneurons (see section III.A.3). The striatum also receives serotonergic afferents from the raphe nucleus that have elicited recent interest with respect to their role in motor control in the normal brain and in Parkinson’s disease (Di Matteo et al., 2008).

Although outside the scope of this review, it is important to recognize that ACh has another target receptor, the muscarinic receptor, that greatly outnumbers nAChRs (Conn et al., 2009). The G-protein-coupled muscarinic receptor exerts a modulatory influence via facilitatory M1-type receptors and inhibitory M2-type receptors, located both presynaptically on corticostriatal and nigrostriatal afferents and somatodendritically on the medium spiny neurons. Inhibitory muscarinic autoreceptors are also present on the cholinergic interneurons to regulate ACh release (Calabresi et al., 2000). In Parkinson’s disease, muscarinic antagonists were one of the first treatments and are still sometimes used in a secondary role (Langmead et al., 2008; Conn et al., 2009). Their efficacy is attributed to a reduction in 1) the overactivity of the cholinergic interneurons and 2) the hyperactivity of corticostriatal glutamatergic neurotransmission that ensues after nigrostriatal denervation. Although they provide some benefit, these drugs are not without side effects, including cognitive impairment. Hence, there is a need for new and improved therapeutics. Any nicotinic agonist therapy will differ from the actions of ACh in its selectivity for nAChRs as well as in its extended pharmacokinetics compared with the highly regulated release of ACh.

B. Substantia Nigra

The dopaminergic neurons projecting to the dorsal striatum are primarily responsible for modulating motor functions and also cognitive aspects of motor learning (Kreitzer and Malenka, 2008). These arise from the A9 group of midbrain dopaminergic neurons, corresponding to the SN pars compacta (Fig. 1). The presence of neuromelanin in these cells gives them their eponymous dark coloration. The number of dopaminergic neurons in each SN pars compacta is estimated at ~7000 per side in the mouse, ~12,000 in the rat, up to 100,000 in monkeys, and more than 200,000 in young humans (Björklund and Dunnett, 2007). In addition to the predominant striatal innervation, some SN neurons innervate cortical and limbic areas. Dopamine is also released locally within the SN and VTA; this somatodendritic release can be modulated by nAChRs (Cheramy et al., 1981; Rahman et al., 2004a). The dendritic arborization extends into the underlying SN pars reticulata, populated with GABAergic neurons. Thus, dendritically released dopamine can influence the activity of dopamine projection neurons themselves via somatodendritic autoreceptors and GABAergic activity within the SN pars reticulata, which forms the output pathway of the direct and indirect circuits (Fig. 3) (Robertson, 1992; Zhou et al., 2009).

The SN pars compacta contains a population of GABAergic interneurons, as well as GABAergic afferents from the striatum, globus pallidus, and SN pars reticulata, that act as a brake on dopaminergic cell activation. Both the GABAergic and dopamine neurons bear nAChRs (Migeld, 2004) (see section III.A.2; Fig. 4b). As already noted, midbrain dopamine neurons exhibit two distinct firing patterns, tonic single-spike activity and burst spike firing (Goto et al., 2007). The switch to burst firing is dependent on glutamatergic innervation, which comes from the subthalamic nucleus and the pedunculopontine nucleus (PPT) (Lee and Tepper, 2009). These glutamatergic nerve terminals may also be endowed with nAChRs (Keath et al., 2007).

C. Pedunculopontine Nucleus

The cholinergic input that provides the ACh to interact with nAChRs in the SN pars compacta comes from the PPT situated in the pons (Figs. 1 and 3). Analogous cholinergic innervation of the VTA is from the related laterodorsal tegmental nucleus. The PPT provides both cholinergic and glutamatergic inputs that synapse onto nigral dopamine neurons (Mena-Segovia et al., 2008) (Figs. 3 and 4b). The convergence of these inputs has raised the possibility that both neurotransmitters may be coreleased from the same terminals, with some evidence that this does occur in the squirrel monkey but not in the rat (Lavoie and Parent, 1994; Wang and Morales, 2009). Stimulation of the PPT elicits burst firing in SN pars compacta dopamine neurons (Lokwan et al., 1999; Floresco et al., 2003) and evokes dopamine release in the striatum, which is inhibited by application of either nicotinic or glutamatergic receptor antagonists into the SN pars compacta (Putami et al., 1995; Forster and Blaha, 2003). Indeed, it has been suggested that cholinergic activation is critical for promoting burst firing (Kitai et al., 1999). This idea resonates with a proposal for the VTA (based on studies with knockout mice lacking particular nAChR subunits) that cholinergic nicotinic activation of dopamine cell bodies serves as a gate that facilitates the switch to burst firing, enabling the dopamine neurons to respond to glutamatergic signals (Maskos, 2008, 2010).

III. Neuronal Nicotinic Acetylcholine Receptors

A. Structure and Heterogeneity

nAChRs are pentameric ligand-gated cation channels, permeable to Na⁺, K⁺, and, to varying degrees, Ca²⁺. The five membrane-spanning subunits create a central pore or channel that is opened in response to binding ACh or
exogenous agonist. Muscle-type nAChRs, found in skeletal muscle and in *Torpedo* spp. electric tissues, have provided detailed insights into the structure and function of the receptor (Unwin, 2003). However, a distinct set of genes coding for neuronal nAChR subunits is expressed in neurons and some non-neuronal cells, including glia (Albuquerque et al., 2009; Millar and Gotti, 2009). To date, nine neuronal nAChR subunit genes have been shown to be expressed in various mammalian CNS neurons (α2–α7; β2–β4). The most abundant and widespread of these are β2, α4, and α7. Others have a more restricted distribution; for example, expression of α6 and β3 subunits is largely limited to catecholaminergic neurons. In addition, α8 has been found only in avian systems, and α9 and α10 are limited to cochlear hair cells, sensory neurons, and some non-neuronal cells. In theory, these subunits could combine to give a huge array of nAChR subtypes. However, the diversity of native nAChR subtypes is more limited, and assembly into viable nAChRs seems to be constrained by a set of presently poorly understood rules.

The simplest subunit combination is a pentamer of identical subunits (Albuquerque et al., 2009; Millar and Gotti, 2009). Of the subunits expressed in the mammalian brain, only the α7 subunit is able to form homomeric nAChRs in expression systems. Most, if not all, native α7 nAChRs are also homomers (Séguela et al., 1993). In contrast, α2–α6 subunits are incapable of forming homomeric receptors and require β subunits (and additional α subunits in the case of α5) for formation of functional nAChRs (Albuquerque et al., 2009; Millar and Gotti, 2009). The agonist binding site occurs primarily on α subunits (“principal binding site”) but is formed at the interface with the adjacent β subunit that also contributes complementary binding residues (“complementary binding site”) (Corringer et al., 2000; Celie et al., 2004). For heteromeric neuronal nAChRs, α2, α3, α4, and α6 subunits can pair with β2 or β4 subunits to create an agonist binding site (see Fig. 4). As demonstrated for muscle-type nAChR, it is assumed that two binding sites per nAChR must be occupied for effective opening of the ion channel. In contrast to β2 and β4, the β3 subunit does not contribute to binding sites but is regarded as an “accessory subunit” that occupies the fifth position in the nAChR, analogous to the β1 subunit in muscle nAChR. The α3 subunit also functions exclusively as an accessory subunit, in that it lacks key residues critical for agonist binding (Kuryatov et al., 2008). Other α and β subunits can occupy the fifth position and form β agonist binding pairs (Fig. 4). Subunit composition determines nAChR properties, including channel open time, ion permeability and selectivity, and rate of desensitization, in addition to agonist sensitivity (Albuquerque et al., 2009; Millar and Gotti, 2009).

The structural diversity of nAChRs is paralleled by the diversity of their localization (at both cellular and tissue levels). Although this review is focused on nAChRs within the basal ganglia, it is important to emphasize that nAChR subtypes occur throughout the central and peripheral nervous systems, as well as on some non-neuronal cells. Thus nAChRs influence many physiological mechanisms, including pain, inflammation, cognition, and others (Bacher et al., 2009; Buckingham et al., 2009; McIntosh et al., 2009; Poorthuis et al., 2009; Sarter et al., 2009; Changeux, 2010a; Mineur and Picciotto, 2010; Philip et al., 2010). As a consequence, systemic nicotine and other agonists have many and varied biological effects, beyond the modulation of motor control.

1. Pharmacological Tools to Study Nicotinic Acetylcholine Receptor Subtypes in the Nigrostriatal System

A host of experimental approaches has been used to identify and study the different nAChR subtypes described in the previous section, including mRNA work, immunoprecipitation with selective nAChR subunit-directed antibodies, and the use of genetically engineered mice. In addition, pharmacological tools have assisted in identification and in characterization of distribution and function. Some of the more common drugs used as investigational tools are described below.

A variety of different agonists and antagonists have been used to study CNS α4β2* nAChRs (* signifies the possible presence of other subunits in the nAChR complex). However, emerging studies suggest that many of these compounds also act at other nAChR subtypes, particularly α6β2* nAChRs. Thus, mecamylamine and dihydro-β-erythroidine, two antagonists frequently used to investigate α4β2* nAChR-mediated function, also block α6β2* nAChRs (Exley et al., 2008; Meyer et al., 2008; Perez et al., 2008). With respect to α4β2* nAChR-directed agonists, 3-[(2S)-2-azetidinylmethoxy]-5-iodopyridine dihydrochloride (5-ido-A-85380) was initially reported to selectively bind to α4β2*, with much lower affinity for α3β4* and α7 nAChRs (Mukhin et al., 2000). However, it was subsequently shown to act with similar potency at both α4β2* and α6β2* nAChRs (Kulak et al., 2002b). Varenicline, a partial α4β2* nAChR agonist, also interacts with α3β4*, α6β2*, and α7 nAChRs (Coe et al., 2005; Gonzales et al., 2006; Jorenby et al., 2006; Rollena et al., 2007a,b; M. Quik, unpublished observations). Sazetidine-A, another agent initially reported as selective for α4β2* receptors, binds with high affinity to α6β2* nAChRs and stimulates both α4β2* and α6β2* nAChR-mediated dopamine release (Xiao et al., 2006; Cucchiaro et al., 2008; Zwart et al., 2008; M. Quik, unpublished observations). In addition, the agonist ABT-089 (pozanicline) (Sullivan et al., 1997) has activity at both α4β2*and α6β2* receptors (Marks et al., 2009). Numerous other drugs in the literature have also been reported to interact with α4β2* nAChRs, including undesignated compounds from Abbott Laboratories (Abbott Park, IL), Targacept, Inc. (Winston-Salem, NC), SIBIA Neurosciences (La Jolla, CA), and University of Bath (Bath, UK). However, at this point, their selectivity is uncertain because their interaction with α6β2* nAChRs and/or other nAChR subtypes is not known (Bencherif et al., 1996; Cosford et al., 1996; Donnelly-Roberts et al., 1996, 1998; Bencherif et al., 2000; Sharples
et al., 2000; Buccafusco et al., 2005; Gotti et al., 2006b; Lippiello et al., 2006; Wang et al., 2006; Dwoskin and Bardo, 2009). All together, these observations indicate that the majority of available α6β2* nAChR drugs may interact with other nAChR subtypes, notably α6β2* nAChRs; at best these agents should be regarded as only β2-selective. However, general β2-selective agonists may have therapeutic advantages, as discussed in section VIII.B (Huang et al., 2011).

A toxin that has proved invaluable in elucidating the nature and function of α6β2* nAChRs is α-conotoxinMII (McIntosh et al., 2004; Quik and McIntosh, 2006). This 16-amino acid peptide, originally isolated from the venom of the marine snail Conus magnus, selectively interacts at α3β2* and α6β2* nAChRs (Cartier et al., 1996; Champaiaux et al., 2002). Because there is little evidence for the existence of α3β2* nAChRs in mouse brain (Whiteaker et al., 2002), α-conotoxinMII provides information specifically concerning α6β2* nAChR in the rodent nigrostriatal pathway. By contrast, α6β2* and a small population of α3β2* nAChRs are present in monkey striatum; thus, α-conotoxinMII would interact at both subtypes (Quik et al., 2005). Another toxin, α-conotoxinPIA from Conus purpurascens, can discriminate between α6* and α3* nAChRs (Dowell et al., 2003; Gotti et al., 2010) but it is not readily accessible. No other toxins, drugs, or agents presently exist that selectively interact with α3β2* and/or α6β2* nAChRs. Thus, discrimination of native nAChRs that have minor differences in subunit composition is currently not possible.

Because selective agonists for α7 nAChRs were not available until more recently, antagonists have been particularly important for the study of these receptors. A key antagonist used to study α7 nAChRs is α-bungarotoxin. This toxin, isolated from the venom of Bungarus multicinctus, binds to α1*, α7, and α9/10 nAChRs (Albuquerque et al., 2009). Because α1* receptors are present only in sketal muscle, and α9/10 receptors are not found in the brain, α-bungarotoxin has proved to be a very selective tool for α7 nAChRs in the CNS. It is used primarily for in vitro studies because it does not cross the blood-brain barrier, although it can be injected intracerebrally. Methyllycaconitine is a small-molecular-weight α7 nAChR antagonist that readily enters the brain when given systemically (Macallan et al., 1988; Ward et al., 1990). However, although selective for α7 nAChRs at low nanomolar concentrations, it interacts with other nAChR subtypes, notably α6β2* nAChRs, at higher concentrations (Mogg et al., 2002). Small-molecular-weight α7 nAChR agonists include 3,3′-(3E)-3,3′-[2,4-dimethoxyphenyl]methylene]-5,6-dihydro-4H-pyrindin-2-yl)pyridine (GTS-21), (4-bromophenyl)-1,4-diazabicyclo[3.2.2]nonane-4-carboxylate (SSR180711), N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-chlorobenzamide (PNU-282987), and (2S)-2′H-spiro[4-azabicyclo[2.2.2]octane-2,5′-[1,3]oxazolidin]-2′-one (AR-R17779) (Levin et al., 1999; Simosky et al., 1998; Martin et al., 2004; Hansen et al., 2007; Söderman et al., 2011). Choline, the breakdown product of ACh, is also found to selectively activate α7 nAChRs at millimolar concentrations (Alkondon et al., 1997). Ambient levels of choline, especially in areas such as striatum, where there are tonically active cholinergic neurons, might be sufficient to maintain α7 nAChRs in a desensitized state. The recent generation of allosteric potentiators, some specific for α7 nAChRs, are valuable additions to the toolbox for enhancing or revealing the contribution of α7 nAChRs (Bertrand and Gopalakrishnan, 2007).

2. Nicotinic Acetylcholine Receptor Subtypes in the Substantia Nigra

Determining the cellular expression of nAChR subunits and the subcellular localization of defined nAChR subtypes poses a major challenge. However, this has proved somewhat easier to address for the nigrostriatal dopamine pathway than for other brain systems, because dopamine afferents are highly localized to this ascending pathway, which can be selectively lesioned by dopaminergic neurotoxins. As well, the striatum and SN are relatively homogeneous with respect to their neuronal makeup and neuronal composition.

In rodents, mRNA for five nAChR subunits, (α4, α5, α6, β2, β3) is expressed at high levels in the SN pars compacta, with lower levels of α7 mRNA (Wada et al., 1989; Marks et al., 1992; Cui et al., 2003). The dopamine neurons and GABAergic interneurons that populate the SN pars compacta can be distinguished by expression of tyrosine hydroxylase or glutamate decarboxylase, respectively, and by their characteristic electrophysiological properties, such as intrinsic membrane potential and firing properties (Grace and Bunney, 1983a,b,c; Lacey et al., 1989). Single-cell reverse transcription-polymerase chain reaction or double-labeling in situ hybridization in combination with these indices of neuronal identity showed that most dopamine neurons express mRNA corresponding to α4, α5, α6, β2, and β3. At a lower level and in a lower proportion of cells, α3 nAChR mRNA was also detected (Klink et al., 2001; Azam et al., 2002). However, α3 subunit expression decreased during development in the rat; this decrease coincided with an increase in α6 subunit expression (Azam et al., 2007). In contrast, SN GABA neurons displayed a simpler expression pattern largely restricted to α4, β2, and α3. In addition, approximately 40% of both dopamine and GABA neurons of the SN expressed mRNA for α7 nAChRs (Klink et al., 2001). β4 mRNA expression was generally low, but higher in nondopaminergic neurons (Klink et al., 2001; Azam et al., 2002). Overall, the pattern of nAChR transcript expression in nonhuman primates resembles that in rodents, except for the α2 mRNA, which is absent in the rodent but present in the primate SN (Han et al., 2000; Quik et al., 2000a,b).

The next challenges were to determine 1) the subunit combinations forming native, functional nAChRs in these neurons and 2) their subcellular disposition (Fig. 4b). Klink et al. (2001) used pharmacological tools and transgenic mice lacking α4 or α7 subunits to analyze nictinic currents elicited from cell bodies of SN dopamine neurons. They interpreted their data in favor of two predominant
somatodendritic subtypes: α4α6β2γδ (sensitive to blockade by α-conotoxinMII) and (α4)β2γδ (insensitive to α-conotoxinMII). The former subtype is distinct from any of those identified in striatum (see below), although more recent immunoprecipitation studies found no evidence for the association of α5 with α6 subunits in midbrain; thus, α4α6β2γδβ3 may be a more likely subunit composition (Gotti et al., 2010). However, Gotti et al. (2010) noted the different complement of nAChR subunit combinations identified in midbrain compared with striatum, suggesting the occurrence of some different nAChR subtypes in somatodendritic and terminal compartments. In addition, typical α7 nAChR-mediated currents could be elicited by cholinoceptin in the lower proportion of dopaminergic neurons (Klink et al., 2001; Keath et al., 2007).

There is little functional evidence that addresses the subunit composition of nAChR on the sparse GABA neurons in the SN pars compacta, although both α7 and non-α7 nAChRs have been localized to the soma and proximal dendrites of GABAergic neurons of the SN pars reticulata (Poisik et al., 2008). In the VTA, the absence of functional responses (other than α7 nAChR responses) in GABAergic neurons in α4 or β2 knockout mice led to the proposition that non-α7 nAChRs are α4β2 and possibly α3α4β2 subtypes (Klink et al., 2001). However, in SN GABA neurons, nAChR subunit expression is more diverse (Klink et al., 2001), and nAChRs on GABA neurons exhibit a different pharmacological profile compared with VTA (Keath et al., 2007), leaving some uncertainty about the exact subunit composition and stoichiometry of the nAChRs present. The conclusion that GABA interneurons in the SN pars compacta, as well as the projection neurons of the SN pars reticulata, are endowed with heteromeric nAChRs that have distinct properties compared with those expressed on dopamine cell bodies is consistent with functional studies described in section III.B.1.

In summary, a large portfolio of nAChR subunits is expressed in the SN pars compacta, which contains the dopaminergic cell bodies. Multiple complex subtypes of nAChR seem to exist in these dopamine neurons, whereas GABA interneurons exhibit a somewhat simpler expression pattern (Fig. 4b). The presence of distinct nAChR subtypes on dopaminergic and GABAergic neurons in the SN has functional implications, in that it may allow nAChR drugs with differing pharmacodynamic profiles to interact preferentially with one or other of these cell types.

3. Nicotinic Acetylcholine Receptor Subtypes in the Striatum

Identification of nAChR subtypes present on dopamine axon terminals projecting to the striatum could not be undertaken at the single cell level. Instead, neurochemical assays of nAChR function have commonly been employed (Grady et al., 2007). These studies have also relied on subtype-selective pharmacological tools and knockout mice, complemented by immunoprecipitation assays using subtype-specific antibodies to pull down nAChR complexes labeled with a radioligand, typically [3H]epibatidine (Gotti et al., 2007). Selective lesioning of the nigrostriatal pathway using 6-hydroxydopamine or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to eliminate dopamine terminals has been used to distinguish this population (Zoli et al., 2002; Quik et al., 2007b). As a whole, this substantial body of work has generated a comprehensive and coherent picture of nAChR subtypes expressed on dopamine terminals, and the heterogeneity is surprising.

First, α3 and α7 subunits do not contribute to presynaptic nAChRs on dopamine terminals in the rodent striatum, despite their expression by some SN pars compacta neurons and their contribution to the population of nAChRs on SN cell bodies (Whiteaker et al., 2002). Conversely, β3 has been credited with contributing only to presynaptic α6α2 nAChRs (Zoli et al., 2002; Cui et al., 2003; Salminen et al., 2004) and may be important for targeting or trafficking nAChRs that include it (Tumikoski et al., 2006). Immunoprecipitation studies found modest amounts of α4α6β2β3 nAChRs in SN, as discussed above (Gotti et al., 2010); it is not known whether these represent functional somatodendritic receptors or nAChRs destined to be trafficked to the striatum. Absence of the β3 subunit in null mutant mice reduces but does not eliminate α6α2 nAChRs (Gotti et al., 2005). Although this observation suggests that β3 is not an obligatory partner of α6, the two subunits have been seen to decrease in parallel after lesions of the nigrostriatal pathway, which would suggest that they are tightly correlated (Zoli et al., 2002; Quik et al., 2003). A parsimonious explanation is that β3 normally combines with α6 for the most efficient assembly, stabilization, and/or trafficking of α6β3* nAChRs, and in its absence only low levels of inefficiently processed α6α2 nAChRs are maintained. The asterisk signifies the possible presence of other subunits in the nAChR complex (see Fig. 4a).

The subunits that are present in presynaptic nAChRs on dopaminergic terminals in rodent striatum include α4, α5, α6, β2, and β3. These comprise 5 subtypes that have been subdivided into two main categories based on their interaction with the snail toxin α-conotoxinMII (McIntosh et al., 1999; Whiteaker et al., 2000) (Fig. 4a). These include those containing the α6 subunit (α4α6β2β3, α6β2β3, α6β2), which are termed α-conotoxinMII-sensitive because they bind α-conotoxinMII. The other class (α4β2, α4α5β2 subtypes) does not contain α6, does not bind α-conotoxinMII, and is designated α-conotoxinMII-insensitive (Zoli et al., 2002; Salminen et al., 2004). Functional measurements have suggested a greater proportion of α6β2* nAChRs in the nucleus accumbens compared with striatum (caudate putamen) (Exley and Cragg, 2008).

nAChR subtype heterogeneity could be further increased by α4β2* and α6β2* nAChRs existing in two stoichiometric forms, as has been shown for heterologously expressed α4β2* nAChRs (Nelson et al., 2003; Moroni et al., 2006) (Fig. 4a). These alternate forms have distinct agonist sensitivities depending on whether α4 or β2 occupies the fifth, accessory position; that is, (α4)α6β2 displays
higher affinity for ACh and nicotine than \((\alpha_4)\beta_2\). With regard to the regulation of dopamine release from striatal terminals, pharmacological evidence in favor of the high-sensitivity \((\alpha_4)\beta_2\) form (Anderson et al., 2009) or both high- and low-sensitivity forms (Grady et al., 2010) has been presented. The interpretation of data for native subtypes is complicated by the high affinity shown by \((\alpha_4)\beta_2\alpha_5\) nAChRs that are also present on dopamine terminals (Grady et al., 2010). The occurrence and functional significance of alternative stoichiometries of \(\alpha 6\beta 2\) nAChRs has not yet been elucidated.

The proportion of \(\alpha\)-conotoxinMII-sensitive to insensitive nAChR subtypes is \(\sim 30:70\) in rodents (Cartier et al., 1996; Kulak et al., 1997; Grady et al., 2007) but this ratio is \(\sim 50:50\) in monkey striatum (Kulak et al., 2002). This might reflect the additional presence of \(\alpha\)-conotoxinMII-sensitive \(\alpha 6\beta 2\) nAChR on nigrostriatal terminals in monkey brain (Quik et al., 2005). After nigrostriatal lesions with either MPTP or 6-hydroxydopamine, \(\alpha 6\) and \(\beta 3\) subunit-containing nAChRs decline in parallel with the loss of dopaminergic markers such as the dopamine transporter (Zoli et al., 2002; Champtaiaux et al., 2003; Cui et al., 2003; Quik et al., 2003, 2005). By contrast, nAChRs composed of \(\alpha 4\) and \(\beta 2\) (but not \(\alpha 6\)) subunits, which can be detected by their ability to bind agonist with high affinity in the presence of \(\alpha\)-conotoxinMII, are much less affected by lesioning in both rodents and primates, such that up to 70% of \(\alpha 4\beta 2\) nAChRs may be spared (Quik et al., 2001; Kulak et al., 2002a; Zoli et al., 2002; Champtaiaux et al., 2003; Quik et al., 2003). An explanation of this anomaly is that expression of the \(\alpha 6\) and \(\beta 3\) subunits is restricted to catecholaminergic neurons, whereas \(\alpha 4\beta 2\) nAChRs also occur on nondopaminergic components of the striatum. However, the high level of residual \(\alpha 4\beta 2\) nAChRs is surprising. The paucity of in situ hybridization signals for expression of nAChR subunits in striatum or caudate putamen is striking (Wada et al., 1989; Marks et al., 1992; Le Novère et al., 1996) and reinforces the notion that the majority of nAChRs in this region is located presynaptically on afferents rather than expressed by intrinsic cells. There is neurochemical evidence for \(\alpha 7\) nAChRs on glutamate afferents (Kaiser and Wonnaeott, 2000; Marchi et al., 2002). nAChRs accounting for 30% of the striatal population of \(\left[^{3}H\right]\text{ACh}\) binding sites (that equate with \(\alpha 4\beta 2\) nAChRs) were reported to occur on serotonin terminals (Schwartz et al., 1984), but this could not be reproduced in a subsequent study (Pradhan et al., 2002). However, nAChRs with a novel pharmacological profile were ascribed to serotonin terminals based on transmitter release studies from synaptosomes (Reuben and Clarke, 2000).

The relationship between nAChRs and serotonergic terminals warrants clarification in view of recent evidence for the sprouting of these afferents in L-DOPA-induced dyskinesia (Rylander et al., 2010).

Medium spiny projection neurons seem to be devoid of nAChRs (Jones et al., 2001; Zhou et al., 2002) but fast-spiking GABA interneurons (which comprise a tiny proportion of the total neuronal population) were shown to respond to the application of ACh or carbachol in a manner consistent with somatodendritic (possibly extrasynaptic) nAChRs (Koós and Tepper, 2002). In an elegant study, photoactivation of optogenetically engineered cholinergic interneurons of the nucleus accumbens resulted in an increased frequency of inhibitory currents in medium spiny neurons, and this response was sensitive to mecamylamine (Witten et al., 2010). The network connections mediating the increased firing rate are unclear, but it is plausible that GABAergic interneurons bearing nAChRs are involved, rather than a direct cholinergic action on medium spiny neurons.

There is also evidence for functional \(\alpha 4\beta 2\) (including \(\alpha 4\beta 5\)) nAChRs on GABAergic terminals from striatum (Grilli et al., 2009; McClure-Begley et al., 2009). These could arise from GABA interneurons, axon collaterals from the medium spiny projection neurons or collateral projections from the GABAergic neurons in the globus pallidus (Bolam et al., 2000).

Cholinergic interneurons might express \(\beta 2\) subunit mRNAs, because \(\beta 2\)-like immunoreactivity was reported in “sparsely distributed large neurons” in the rat striatum that might correspond to cholinergic interneurons (Hill et al., 1993; Azam et al., 2003). On the other hand, Jones et al. (2001) did not detect any \(\beta 2\) immunolabeling of cell bodies in striatum. Functional studies support the presence of muscarinic but not nAChRs on the cell bodies of cholinergic interneurons (Calabresi et al., 1998; Windels and Kiyatkin, 2003). Moreover, there are conflicting reports of presynaptic nicotinic modulation of ACh release in striatum with positive results reported by some (Sandor et al., 1991; Yu and Wecker, 1994) but not others (Araujo et al., 1988).

One study reported MLA-sensitive nicotine-evoked currents, consistent with \(\alpha 7\) nAChRs, in a proportion of medium spiny neurons, fast-spiking interneurons, and cholinergic interneurons in mouse striatum (Xiao et al., 2009). This is consistent with the finding of \(\alpha 7\) subunit mRNA in some rat striatal cholinergic interneurons (Azam et al., 2003). However, levels of \(\left[^{125}\text{I}\right]\alpha\)-bungarotoxin binding in striatum are generally low, although higher in mouse than rat, indicative of only low levels of this nAChR subtype (Marks et al., 1986).

In summary, dopamine terminals in the striatum express a remarkable diversity of nAChRs, with the \(\alpha 4\beta 2\) and \(\alpha 6\beta 2\) nAChR subtypes studied most extensively. The \(\alpha 6\beta 2\) nAChRs are unique to dopamine terminals in striatum, whereas \(\alpha 4\beta 2\) nAChRs are more promiscuous and are localized to dopamine terminals and other neuronal elements. Much less is known about the latter category of \(\alpha 4\beta 2\) nAChRs with respect to their subunit composition and cellular localization, but their resistance to nigrostriatal degeneration makes it important to understand this population better. There is also little information about striatal \(\alpha 7\) nAChRs. In addition, the role of \(\alpha 3\beta 2\) nAChRs,
present on nigrostriatal terminals in primates but not found in rodent striatum, remains to be identified.

**B. Nicotinic Acetylcholine Receptor Modulation of Dopaminergic Function**

**I. Substantia Nigra**

As mentioned in section II.B, SN dopamine neurons exhibit a tonic pacemaker activity, with regular firing of action potentials (Grace and Bunney, 1984a,b). Cholinergic inputs from the PPT regulate the activity of dopamine neurons (Mena-Segovia et al., 2008). Early studies in rats recognized that systemic nicotine increased the firing rate of SN pars compacta neurons (Lichtensteiger et al., 1982; Clarke et al., 1985) and promoted burst firing (Greenhoff et al., 1986). These findings have been recapitulated in a recent study (Zhang et al., 2009b). Iontophoretic application of ACh in the SN pars compacta also enhanced firing, and this was inhibited by dihydro-β-erythroidine but not atropine, implicating a nicotinic, rather than muscarinic, receptor-mediated response (Lichtensteiger et al., 1982). These studies suggested a direct excitatory action of nicotine on SN dopamine neurons, mimicking the endogenous cholinergic innervation from the PPT (Clarke et al., 1987). However, the excitability of dopamine neurons is restrained by GABAergic inputs and influenced by glutamatergic afferents (Misgeld, 2004; Lee and Tepper, 2009). The presence of nAChRs on these elements as well as on dopamine cell bodies and dendrites (Fig. 4b) presents a more complex scenario for the nicotinic regulation of dopamine cell activity.

The nicotinic regulation of SN pars compacta dopamine cell firing has been studied much less extensively than that in the VTA, reflecting interest in the mesolimbic “reward” pathway with respect to nicotine dependence. This observation also marks another limitation in the field, in that there has been greater emphasis on the actions of the exogenous drug nicotine than on the endogenous cholinergic mechanisms governing physiological function. Nevertheless, given the comparable firing patterns (Zhang et al., 2009b) and similarities in the neurochemical interactions and disposition of nAChRs in the VTA and SN (Livingstone and Wonnacott, 2009) and comparable, albeit pharmacologically distinct, nicotinic modulation in the VTA and SN (Keath et al., 2007), it can be argued that similar mechanisms are likely to operate in the two regions. With these caveats, we can propose a model for the SN pars compacta analogous to that proposed for the VTA (McKay et al., 2007), in which activation of β2* nAChRs on dopamine neurons increases firing rates. Concomitant desensitization of distinct β2* nAChRs on GABA interneurons, with a resultant decrease in inhibitory input onto the dopamine cells, would enhance the activation of dopamine neurons.

The propensity of β2* nAChRs on GABA interneurons to desensitize more rapidly than those on dopamine cell bodies (Yin and French, 2000) is presumed to reflect subtle differences in their subunit composition, local environ-
lamic nucleus, as well as the PPT, do induce burst firing, mainly via NMDA receptors, in an fashion analogous to that of the prefrontal cortex inputs to the VTA (Lee and Tepper, 2009).

The relative contributions of \( \alpha 7 \) and \( \beta 2 \) \( \alpha \) subunits and null mutant mice lacking the \( \beta 2 \) or \( \alpha 7 \) subunit, and interpretations were confirmed by lentiviral re-expression of the absent \( \beta 2 \) subunit. Spontaneous firing rate and firing pattern in wild-type animals could be classified into four categories: low firing/low bursting, low firing/high bursting, high firing/low bursting, or high firing/high bursting. \( \beta 2 \) subunits (and hence \( \beta 2 \) \( \alpha \) subunits) were essential for high frequency rates of firing and/or bursting. It is suggested that \( \beta 2 \) \( \alpha \) subunits could provide sufficient depolarization for activation of NMDA receptors, functioning as a “switch” or “gate” between basal and excited states (Mameli-Engvall et al., 2006; Ungless and Cragg, 2006). \( \alpha 7 \) \( \alpha \) subunits seemed to have a more subtle role, as both low-firing/low-bursting and high-firing/high-bursting states were observed in \( \alpha 7 \) knockout mice, but the intermediate states were absent (Mameli-Engvall et al., 2006). How presynaptic \( \alpha 7 \) \( \alpha \) subunits on glutamate afferents versus somatodendritic \( \alpha 7 \) \( \alpha \) subunits on dopamine neurons differentially shape these responses is unknown.

In summary, the activity of dopamine neurons in the SN pars compacta is driven, in part, by cholinergic input from the PPT. Evidence from the VTA suggests that somatodendritic \( \beta 2 \) \( \alpha \) subunits (notably \( \alpha 6 \beta 2 \) \( \alpha \) subunits that are confined to the dopaminergic neurons) mediate the principal effects of ACh, and play a critical, permissive role with respect to facilitating responses to glutamatergic inputs (Masksos, 2008). \( \alpha 7 \) \( \alpha \) subunits exert a more subtle influence. Presynaptic \( \alpha 7 \) \( \alpha \) subunits on glutamate afferents may contribute to burst firing and synaptic plasticity. The significance of somatodendritic \( \alpha 7 \) \( \alpha \) subunits on a proportion of dopamine neurons is presently unclear. The activity of dopamine neurons is constrained by GABA afferents and local interneurons; nicotine (but not tonically released ACh) preferentially desensitizes \( \alpha 4 \beta 2 \) \( \alpha \) subunits on GABA interneurons, relieving this inhibition. In addition, bursting in SN pars compacta neurons may also be influenced by the autoinhibitory actions of dendritically released dopamine (Pucak and Grace, 1994), which is also subject to nicotinic modulation (Reuben and Clarke, 2000; Rahman et al., 2004a; Rahman et al., 2004b).

2. Striatum

The consequence of SN pars compacta dopamine neuron activity is the release of dopamine in the striatum. The tonic firing of single action potentials (typically at a frequency of 1–5 Hz) maintains low, nanomolar concentrations of extracellular dopamine (Goto et al., 2007). Burst firing, which accompanies behaviorally salient stimuli, produces proportionately much greater release of dopamine, achieving local transient concentrations in the micromolar to millimolar range. As discussed in section II.C, cholinergic input from the PPT is a determinant of burst firing, and direct stimulation of the PPT elicits striatal dopamine release via nigral nicotinic and glutamate receptors (Forster and Blaha, 2003). Thus, physiologically, striatal dopamine release is largely driven by action potentials generated in the cell bodies of the SN pars compacta. However, levels of extracellular dopamine also depend on terminal release efficiency, diffusion and spillover from the synapse versus reuptake by dopamine transporters, and regulation via autoreceptors and other inputs (Zhang et al., 2009). It is in this context that striatal \( \alpha \) subunits contribute.

Dopaminergic terminals in the striatum are well endowed with a distinct population of \( \beta 2 \) \( \alpha \) subunits (Fig. 4a), and much attention has focused on \( \alpha \) subunit-mediated dopamine release in vitro. The use of striatal synaptosome or chopped tissue preparations clearly demonstrated the ability of presynaptic \( \alpha \) subunits to promote \( Ca^{2+} \) dependent dopamine release in the absence of any other depolarizing stimulus (Wonnacott, 1997; Grady et al., 2007). Using knockout mice lacking specific subunits and pharmacological tools, at least five subtypes of \( \beta 2 \) \( \alpha \) subunits were found to contribute to striatal dopamine release (Fig. 4a). The \( \alpha 4 \alpha 6 \beta 2 \beta 3 \) subtypes are deduced to have the highest sensitivity (EC\(_{90}\) for nicotine-evoked \([\alpha H]dopamine release was 230 nM) (Salminen et al., 2004, 2007). The presynaptic nicotinic modulation of dopamine release demonstrated by using radiolabeled transmitter has been corroborated for endogenous dopamine using fast-scan cyclic voltammetry (Zhou et al., 2001; Rice and Cragg, 2004; Zhang and Sulzer, 2004; Exley et al., 2008; Meyer et al., 2008; Perez et al., 2008).

Superfusion of isolated nerve terminals (that precludes neurochemical cross talk between boutons) has generally failed to demonstrate any contribution from \( \alpha 7 \) \( \alpha \) subunits that are considered to be absent from these terminals. However, in rat striatal slice preparations some local anatomical integrity is preserved that permits neurochemical cross talk, \( \alpha 7 \) \( \alpha \) subunits have been shown to enhance \([\alpha H]dopamine release (Kaiser and Wonnacott, 2000). This action is absent in striatal tissue from \( \alpha 7 \) knockout mice (Quarta et al., 2009) and is blocked by inhibitors of ionotropic glutamate receptors, consistent with the localization of \( \alpha 7 \) \( \alpha \) subunits on glutamate afferents (Kaiser and Wonnacott, 2000; Marchi et al., 2002; Livingstone and Wonnacott, 2009). There are elaborate reciprocal interactions between dopamine and glutamate afferents in the striatum (Calabresi et al., 1998; Avshalumov et al., 2008). However, no contribution from \( \alpha 7 \) \( \alpha \) subunits was detected in measurements of endogenous dopamine release evoked by low- or high-frequency stimulation in mouse striatal slices (Zhou et al., 2001; Exley and Cragg, 2008).

Presynaptic \( \beta 2 \) \( \alpha \) subunits seem to act by depolarizing the terminal bouton. This leads to activation of voltage-operated \( Ca^{2+} \) channels and influx of \( Ca^{2+} \) (in addition to some \( Ca^{2+} \) entry through the \( \alpha \) subunit channels), and do-
pamine release occurs by classic exocytosis (Soljakov and Wonnacott, 1997; Kulak et al., 2001). The voltage dependence and inward rectification of neuronal nAChRs means that these receptors generate the biggest responses at resting or hyperpolarized membrane potentials (Mulle et al., 1992). Given that dopamine neurons are tonically active, the responsiveness of nAChRs during this pacemaker activity may be compromised. However, local application of nicotine into the striatum of conscious freely moving rats provokes dopamine overflow, consistent with the ability of presynaptic nAChRs to exert a positive effect in vivo (Toth et al., 1992; Marshall et al., 1997). Nevertheless, it is clear from the previous section that midbrain nAChRs drive burst firing, and under bursting conditions (which result in greater terminal depolarization), it may be anticipated that presynaptic nAChRs will show diminished responsiveness to agonist.

Most of the in vitro studies cited so far have focused on the actions of exogenous agonists, notably nicotine, on pharmacologically defined nAChR subtypes in the striatum, with the goal of exploring the actions of psychomotor stimulants. However, in the context of understanding Parkinson’s disease, it is important to comprehend the physiological modus operandi of nAChRs. In the striatum, nAChRs will respond to ACh released from cholinergic interneurons; these are tonically active when dopamine neurons are quiescent (tonic firing) but shut down when dopamine neurons switch to burst firing mode (Cragg, 2006). To better understand the physiological impact of presynaptic nicotinic modulation, dopamine release has been explored in slice preparations in which the endogenous firing patterns of dopamine neurons can be simulated by electrical stimulation (Zhou et al., 2001; Rice and Cragg, 2004; Zhang and Sulzer, 2004; Exley et al., 2008; Meyer et al., 2008; Perez et al., 2008). In these studies, detection of dopamine using carbon fiber microelectrodes and fast-scan cyclic voltammetry combines sensitivity with high temporal and spatial resolution. At low-frequency stimulation, dopamine release as a result of the activation of presynaptic nAChRs by endogenous ACh was indicated by the inhibitory effects of vesamicol, to deplete ACh stores, or nAChR antagonists (Zhou et al., 2001). The decreased amounts of dopamine found in response to ambenonium, an acetylcholinesterase inhibitor, were presumed to reflect nAChR desensitization by the sustained concentration of ACh under these conditions. In agreement with this model, bath-applied agonist (including ACh) decreased evoked release. This distinction is important: it emphasizes that presynaptic nAChRs will show diminished responsiveness to agonist.

The observation by Zhou et al. (2001) that under conditions of low frequency stimulation, nicotine seems to act like a blocker has been confirmed and extended by others (Rice and Cragg, 2004; Zhang and Sulzer, 2004; Exley and Cragg, 2008). Comparison of the effects of nicotine or mecamylamine at a range of stimulation frequencies revealed that although both drugs suppressed release at tonic frequencies (<10 Hz), they enhanced release by phasic bursts (>25 Hz) (Rice and Cragg, 2004; Zhang and Sulzer, 2004; Exley and Cragg, 2008). Similar effects were reported for primate striatal slices (Perez et al., 2009). Thus, inhibition of nAChRs (by desensitization or antagonist) serves to enhance the contrast between levels of dopamine evoked by phasic versus tonic stimulation. This unexpected result has been explained by the occurrence of use-dependent, short-term depression of dopamine release probability at rapidly successive pulses (Cragg, 2003; Rice and Cragg, 2004; Zhang and Sulzer, 2004). At low-frequency stimulation, endogenous ACh increases release probability by activating nAChRs. However, this leads to short-term depression and less release per pulse in response to high-frequency stimulation (bursts). Reducing nAChR activation (by desensitization or antagonist) decreases short-term depression, permitting a greater response to emerge at higher frequencies. What is missing from this picture is the endogenous behavior under bursting conditions, when cholinergic interneurons are coordinately regulated to cease firing (referred to as a “pause”). Thus, ACh will not be released and nAChRs will not be activated. The consequent decrease in nicotinic stimulation is also predicted to decrease short-term depression and enhance the contrast between the two firing patterns. This mechanism has been referred to as a “cholinergic filter” (Rice and Cragg, 2004; Zhang and Sulzer, 2004) that may represent a unique nicotinic mechanism, because inhibiting dopamine autoreceptors or transporters failed to alter the ratio of phasic/tonic dopamine responses despite increasing dopamine release (Zhang et al., 2009a). A potential limitation of this in vitro model is that it is presently uncertain how cholinergic activity changes in response to manipulation of firing patterns experimentally in slice preparations and whether this replicates the “pause” observed in vivo.

The β2-selective antagonist dihydro-β-erythroidine mimics the effects seen with mecamylamine, confirming that β2* nAChRs account for this phenomenon (Zhou et al., 2001; Rice and Cragg, 2004; Zhang and Sulzer, 2004). The contribution of the α6β2* nAChR subpopulation was dissected using the α6β2* selective antagonist α-conotoxin-MII (Exley et al., 2008; Meyer et al., 2008; Perez et al., 2008). In mouse, α6β2* and α4(α6)β2* nAChRs were distinguishable by their sensitivity to stimulus intensity, responding to low and high stimulus strengths, respectively. This result prompted the speculation that these nAChR subtypes may be localized to separate dopaminergic fibers, although it is possible they are expressed on the same fibers but have different sensitivity to acetylcholine such that weak stimulation elicits less acetylcholine release than strong stimulation (Meyer et al., 2008). The contributions of α4(α6)β2* and α6β2* nAChRs were
found to vary with experimental parameters, the latter
appearing to have a lesser impact under phasic stimula-
tion conditions (Exley et al., 2008; Meyer et al., 2008; Perez
et al., 2008). Comparison of responses across the mouse
striatum indicated that α6β2* nAChRs exerted a more
prominent effect on the nicotinic “filter” that modulates
dopamine release in nucleus accumbens (ventral striatum)
that in caudate putamen (dorsal striatum) (Exley et al.,
2008). In primates, α6/α3β2* nAChRs seemed equally
effective in both striatal regions when dopamine release was
evoked by a single stimulus, accounting for at least 80% of
the nicotinic modulation (Perez et al., 2009). In contrast,
when stimulation was delivered as a train of four pulses to
simulate a burst, dopamine release with α6/α3β2* nAChR
blockade was overcome in the dorsal but not ventral stria-
tum from monkeys (Perez et al., 2009). These data demon-
strate that α6β2* nAChRs differentially control dopamine
release in these two regions.

In a comparison of dorsal and ventral striatum, and the
nucleus accumbens shell, Zhang et al. (2009b)) showed that
the dorsal striatum displays a higher probability of
release in response to a single stimulus, representing tonic
(low-frequency) stimulation in both primates (Cragg, 2003)
and rodents (Zhang et al., 2009b). Consequently, this re-
region showed less frequency-dependent facilitation (deter-
mined as the ratio of responses to 20 pulses/1 pulse, deliv-
ered at 10 Hz). Blockade of β2* nAChRs, dopamine
transporters or D2 receptors indicated that nAChRs are
primarily responsible for the differential frequency depen-
dence of dopamine neurons in the dorsal striatum. Whereas these studies (Zhang et al., 2009b) did not con-
sider the contribution of particular β2* nAChR subtypes,
Drenan et al. (2010) found that a gain-of-function mutation
in the α6 nAChR subunit changed the pattern of stimulus-
dependent dopamine release to one that more closely
resembled that found in ventral striatum. The mutant mice
showed reduced synaptic depression and increased fre-
quency-dependent facilitation (the ratio of responses to
disseminated to four pulses/one pulse, delivered at 100 Hz) in dorsal stria-
tum slices, compared with results from wild-type mice.
Moreover, the kinetics of the dopamine waveforms were
altered. One interpretation of this study is that presynap-
ic α6α4β2* nAChRs have a major role in locally shaping
dopamine release in the striatum, but alternative explana-
tions are possible, and it should be remembered that the
gain of function mutation creates a nAChR with consid-
erably altered activity. Indeed, many factors could account
for these observed changes, including adaptive alterations
during development of the mutant animals.

The impact of α7 nAChRs (presumed to reside on glutam-
ate afferents to the striatum) on nicotinic filtering of
dopamine release has received less attention. Antagonism of
α7 nAChRs had no effect on dopamine release in re-
response to low- or high-frequency stimulation of mouse stri-
tatal slices (Zhou et al., 2001), but recent studies in rat
striatal slices revealed a subtle contribution of α7 nAChRs
to nicotinic modulation at high-frequency stimulation (Sei-
pel and Yakel, 2010). The integration of multiple transmitter
influences (including GABA, glutamate, and serotonin)
that may be modulated by presynaptic nAChRs and their
local impact on dopamine release is not yet understood.

In summary, although the firing pattern exhibited by
dopamine neurons is the major determinant of dopamine
release probability in the striatum, evidence is emerging
that the multiplicity of heteromeric nAChR subtypes on
dopamine terminals is important for locally shaping dopa-
mine responses. Presynaptic nAChRs are proposed to act
as filters to interpret dynamic ACh signals that are recip-
rocally coordinated with dopamine neuron firing. Thus
nAChRs serve to discriminate tonic and phasic patterns of
stimulation. Nicotinic drugs can amplify this discrimina-
tion, but they do this by nAChR desensitization or inhibi-
tion, such that nicotinic agonists achieve the same effect as
antagonists. Both α4β2* and α6β2* nAChRs contribute
to the regulation of striatal dopamine release, with the α6β2*
nAChR population playing a dominant role in the nucleus
accumbens and also making a significant contribution in
the striatum. These observations have implications for the
development of drugs with optimal benefit for Parkinson’s
disease.

C. Downstream Dopaminergic Signaling Mechanisms
Linked to Nicotinic Acetylcholine Receptors

The concept that different populations of striatal me-
dium spiny projection neurons are responsible for distinct
aspects of motor control resulted in the classification of the
“direct” and “indirect” pathways (Albin et al., 1989; Gray-
biel et al., 1990; Parent, 1990) (Fig. 3). These circuits act in
an opposing fashion with the direct pathway, resulting in
inhibition of the thalamus or brain stem nuclei, whereas the indirect pathway exerts an inhibitory influ-
ence. The nigrostriatal dopaminergic inputs differentially
regulate these two pathways through the segregation of
dopamine D1 and D2 receptors to medium spiny neurons
of the direct and indirect pathways, respectively (Gerfen
et al., 1990). Thus, in simplistic terms, dopamine acting via
stimulatory D1 receptors serves to enhance disinhibition,
whereas its actions through inhibitory D2 receptors de-
crease inhibition. The net effect is the relief of the brake
on thalamocortical drive to the motor cortex, favoring the
initiation or smooth execution of motor function. This is
consistent with the bradykinesia characteristic of Parkin-
son’s disease when the ‘permissive’ nigrostriatal projection
degenerates. Therapies predicted to boost dopamine re-
lease in the striatum, for example agonists targeting α4β2*
or α6β2* nAChRs, would help to counteract the “brake.”
Therefore, it is of interest to understand the impact of
nAChR regulation on downstream dopamine receptor-
linked mechanisms within the postsynaptic neurons.

In medium spiny neurons of the striatum an important
site of signal integration that is potentially modulated by
nAChRs is the protein DARPP-32. Multiple signaling
pathways converge to regulate this “molecular switch,”
identified as dopamine and cAMP regulated phosphopro-
tein with molecular weight 32 kDa (DARPP-32) (Svenningsson et al., 2004) (Fig. 5). The activity of DARPP-32 is promoted or reduced by dopamine acting via D1 or D2 receptors, respectively. DARPP-32 is expressed in both striatonigral (“direct”) and striatopallidal (“indirect”) neurons and its selective deletion in these subsets of neurons results in decreased and increased locomotor function, respectively. This is consistent with the proposed roles of the direct and indirect pathways and establishes a contribution of DARPP-32 signaling to this regulation (Bateup et al., 2010).

DARPP-32 is a key determinant of medium spiny neuron excitability by virtue of its ability to regulate the phosphorylation status of various targets (including receptors, ion channels, and transcription factors) through the inhibition of the multifunctional protein phosphatase 1 (PP-1). D1 receptor stimulation is reported to increase currents through α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors and L-type Ca\(^{2+}\) channels in striatal neurons, and this depends upon DARPP-32 inhibition of PP-1 (Surmeier et al., 1995; Yan et al., 1999). DARPP-32 knockout mice lack the ability to produce D1 receptor-mediated potentiation of NMDA-evoked currents (Flores-Hernández et al., 2002). Selective deletion of DARPP-32 in striatonigral or striatopallidal neurons results in functional deficits in long-term potentiation in both neuronal populations (Bateup et al., 2010).

nAChR stimulation is predicted to influence the excitability of postsynaptic striatal neurons via increases in dopamine release (Fig. 5). Indeed, in vivo administration of psychomotor stimulants, including nicotine, that promote dopamine release have been shown to increase DARPP-32 phosphorylation and activation of extracellular signal-regulated kinase in a subset of striatal medium spiny neurons (Valjent et al., 2005). Nicotine increased the phosphorylation of striatal DARPP-32 at multiple sites in mice given systemic injections of nicotine (Zhu et al., 2005). In rat striatal slices in vitro, nicotine has been reported to modify DARPP-32 phosphorylation in a concentration- and time-dependent manner, by acting at β2\(^*\) and α7 nAChRs (Hamada et al., 2004; Hamada et al., 2005). Sensitivity to dopamine receptor antagonists supports the view that nicotine-evoked changes in DARPP-32 phosphorylation depend on dopamine release. It is unclear whether the same or different changes occur in striatonigral and striatopallidal neurons, although the observation of distinct dopamine D1 and D2 receptor-mediated responses is consistent with their segregation.

The therapeutic efficacy of L-DOPA in Parkinson’s disease relies on the preservation of normal postsynaptic signaling mechanisms. The evidence from animal models of the disease, as well as neurochemical assessment of post mortem human brain tissue from patients, suggests that levels of DARPP-32 are unchanged after nigrostriatal denervation (Raisman-Vozari et al., 1990; Nishino et al., 1993). However, functional changes in DARPP-32 may still ensue; for example, increased phosphorylation of DARPP-32 at the inhibitory Thr75 site (with no change in phosphorylation of the activating Thr34 site) has been reported (Brown et al., 2005). DARPP-32 signaling is also implicated in the development of L-DOPA-induced dyskinesia (Santini et al., 2007) (see section VIII.A below).

In summary, the control of motor function via the balance of activity in the direct and indirect pathways projecting from the striatum is influenced by dopamine acting at dopamine D1 and D2 receptors, respectively. The ability of dopamine to modify activity within the medium spiny neurons is achieved, at least in part, via shifts in the balance of phosphorylation and dephosphorylation manipulated by the key regulator protein DARPP-32, an inhibitor of PP-1. DARPP-32 integrates signals from nigrostriatal and other inputs (notably the corticostriatal afferents that release glutamate onto medium spiny neurons) to regulate excitability and longer lasting functions, including synaptic plasticity in the projection neurons. Nicotinic stimulation (studies to date have mostly focused on nicotine) can influence DARPP-32 signaling, predominantly by promoting dopamine release via α4β2\(^*\) and α6β2\(^*\) nAChRs, although α7 nAChR-mediated glutamate release has also been implicated in vitro, at higher nicotine concentrations (Hamada et al., 2004). More studies are needed to elaborate the effects of selective nAChR activation on postsynaptic molecular mechanisms. The ability of nAChRs to influence signaling within the direct and indirect pathways is compatible with their therapeutic potential for treating Parkinson’s disease.

Fig. 5. Pivotal role of DARPP-32 in postsynaptic signaling in medium spiny neurons, illustrating the potential for nicotinic modulation. DARPP-32 integrates inputs from multiple systems to regulate PP-1; only dopamine and glutamate receptors are shown for clarity. Postsynaptic dopamine D1 and D2 receptors are largely segregated to the “direct” (striatonigral) and “indirect” (striatopallidal) projection pathways, respectively. Other components shown are presumed to be common to all medium spiny neurons. DARPP-32 via PP-1 influences the activity of numerous target proteins, including receptors, ion channels and transcription factors. nAChRs that modulate dopamine release, notably α4β2\(^*\) and α6β2\(^*\) subtypes (shown here on nigrostriatal terminals but also present on dopaminergic cell bodies in the SN) can also affect postsynaptic excitability and synaptic plasticity through these mechanisms.
IV. Long-Term Regulation of Nicotinic Acetylcholine Receptors Expression and Function

A. Effect of Long-Term Nicotine Administration

Before nicotine can be used therapeutically for neurodegenerative disorders, it is important to understand the long-term consequences of its administration on nAChR subtype expression and function. As mentioned earlier, short-term exposure results in numerous biological responses because nicotine acts in diverse tissues throughout the body and interacts with different nAChR subtypes at a given site. Repeated administration adds an additional layer of complexity because of receptor desensitization, tolerance, sensitization, up-regulation, and down-regulation. (Corringer et al., 2006; Quik and McIntosh, 2006; Lai et al., 2005; McCallum et al., 2006; Mugnaini et al., 2006; Perry et al., 2007; Moretti et al., 2010). To add to the complexity, the α6β2* nAChR subtypes present in striatum (Fig. 4a) are themselves differently affected by nicotine treatment. Studies with the novel α-conotoxinMII analog E11A, which discriminates between α4α6β2β3 and α6β2β3 subtypes, show that nicotine treatment selectively decreased the former but increased the latter population in mouse striatum (Perez et al., 2008). This up-regulation of α6β2β3 nAChRs is in agreement with expression studies in culture that also show that α6β2 or α6β2β3 receptors are up-regulated with long-term nicotine exposure (Tumkosit et al., 2006; Walsh et al., 2008). It should be noted, however, that these differential nicotine-induced changes in mouse α6α4β2β3 and α6β2β3 subtypes did not occur in rat striatum, suggesting it may be species-dependent or possibly related to differences in treatment paradigms between rats and mice (Perez et al., 2008; Huang et al., 2009).

Another nAChR present in striatum is the α7 subtype (Fig. 4a). Its functional role is less clear because studies are confounded by the very low expression of α7 nAChRs in rat, monkey, and human striatum. However, it is readily detected in mouse striatum, where it may be increased or not affected by nicotine administration (Pauly et al., 1991; Lai et al., 2005; Moretti et al., 2010). These variable results may reflect a requirement for higher concentrations of nicotine to up-regulate α7 nAChRs compared with α4β2* nAChRs.

The molecular basis for the differential regulation of various striatal nAChR subtypes is an area actively under investigation, the α4β2* nAChR subtype being most extensively investigated to date (Govind et al., 2009; Lester et

<table>
<thead>
<tr>
<th>nAChR Subtype</th>
<th>Effect of Nicotine Treatment</th>
<th>System</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>α6β2*</td>
<td>↓ or No change</td>
<td>Rats, mice, monkeys</td>
<td>Lai et al., 2005; Mugnaini et al., 2006; Perry et al., 2007; Moretti et al., 2010; but see Parker et al., 2004</td>
</tr>
<tr>
<td>α6α4β2β3</td>
<td>↓</td>
<td>Rats, mice</td>
<td>Perez et al., 2008; Huang et al., 2009</td>
</tr>
<tr>
<td>α6β2β3</td>
<td>↑</td>
<td>Mice, cultured cells</td>
<td>Tumkosit et al., 2006; Perez et al., 2008; Walsh et al., 2008</td>
</tr>
<tr>
<td>α6β2β3</td>
<td>↑</td>
<td>Rats</td>
<td>Huang et al., 2009</td>
</tr>
<tr>
<td>α3β2</td>
<td>No change</td>
<td>Rats, mice, monkeys</td>
<td>Moretti et al., 2010</td>
</tr>
<tr>
<td>α4β2</td>
<td>↑</td>
<td>Rats, mice, monkeys</td>
<td>Marks et al., 1983; Schwartz and Kellar, 1983; Benwell et al., 1988; Perry et al., 1999; McCallum et al., 2006; Staley et al., 2006; Xiao et al., 2009; Moretti et al., 2010</td>
</tr>
<tr>
<td>α4α5β2</td>
<td>No change</td>
<td>Rats</td>
<td>Moretti et al., 2010</td>
</tr>
<tr>
<td>α7</td>
<td>↑ or No change</td>
<td>Rats, mice, monkeys</td>
<td>Pauly et al., 1991; Quik et al., 2000a; Lai et al., 2005; Moretti et al., 2010</td>
</tr>
</tbody>
</table>
There is a consensus that up-regulation of α4β2* nAChRs is primarily controlled at the post-transcriptional level, with little change in α4 or β2 nAChR mRNA levels (Marks et al., 1992). Various mechanisms have been proposed to explain nicotine-mediated up-regulation (Picciotto et al., 2008; Buccafusco et al., 2009; Benowitz, 2010; Changeux, 2010b; Mao and McGehee, 2010). One hypothesis is that the initial receptor desensitization contributes to up-regulation, possibly via receptor phosphorylation (Léna and Changeux, 2010b; Mao and McGehee, 2010). More recently, it has been proposed that nicotine acts as a chaperone to promote maturation of α4 nAChR subunit precursors that might otherwise be degraded by currently unidentified endogenous molecular components (Sallette et al., 2005; Corringer et al., 2006; Tumkosit et al., 2006; Kuryatov et al., 2008; Walsh et al., 2008; Lester et al., 2009; Jones et al., 2010). The enhanced incorporation of α4 subunits into the α4β2 nAChR may subsequently influence agonist-mediated regulation of other nAChR subtypes. For instance, the enhanced formation of α4β2 receptors may reduce free α4 subunit levels, resulting in a decline in the α6α4β2β3 receptor subtype. By contrast, α6β2β3 receptor levels may still increase because they do not require the α4 subunit. The presence of the β3 subunit in α6β2* nAChRs also increases receptor up-regulation (Tumkosit et al., 2006). Receptor up- and down-regulation is not only controlled by the nature of the subunits in the nAChR complex but is also influenced by chaperone proteins, such as RIC-3, neurexin1β, VLIP-1, and others (Wanamaker and Green, 2007; Millar, 2008; Cheng et al., 2009; Zhao et al., 2009). As well, work suggests that the ubiquitin-proteasome system regulates the stability of neuronal nAChRs with a resultant receptor up-regulation (Rezvani et al., 2010). Numerous mechanisms thus exist to modulate receptor expression and responsiveness with long-term nAChR drug administration.

A balance between these differing molecular mechanisms would ultimately determine the short- and long-term consequences of nicotinic drugs on nAChR subtype expression. This in turn would control nAChR-mediated behaviors linked to Parkinson’s disease, such as locomotor activity.

### B. Effect of Nigrostriatal Damage

As briefly indicated (section III.A.3), damage to the nigrostriatal dopaminergic pathway has a major impact on nAChR expression in striatum in parkinsonian animal models (Schwartz et al., 1984; Quik et al., 2001, 2003; Kulak et al., 2002a; Zoli et al., 2002; Chaptiaux et al., 2003) and in Parkinson’s disease cases (Aubert et al., 1992; Perry et al., 1995; Court et al., 2000; Quik et al., 2004; Bohr et al., 2005; Gotti et al., 2006a). There seems to be a particularly pronounced decline in α6β2* nAChRs, losses paralleling those in the dopamine transporter, a well-established marker of striatal dopaminergic terminals (Table 2) (Quik et al., 2001, 2003; Zoli et al., 2002). These data provide one of the pieces of evidence that α6β2* nAChR are primarily located on incoming dopaminergic afferents to the striatum (Fig. 4a). Further work done with α-conotoxin E11A, a toxin that discriminates between α6β2* nAChR subtypes, showed that the α4α6β2β3 receptor is the first to be lost with nigrostriatal damage, with decreases in the α6β2β3 receptor subtype only with more severe lesioning (Bordia et al., 2007). This pattern of decline is observed across species (mice, rats, monkeys, humans), highlighting the possibility that the α4α6β2β3 receptor subtype may identify a particularly vulnerable population of dopaminergic afferents to the striatum.

By contrast to the dramatic declines in α6β2* nAChRs with nigrostriatal damage, the decrease in the α4β2* nAChR population that does not include α6 is much less severe (Table 2). The reason for the apparently smaller decline in the α4β2* receptor subtype most likely relates to its more diverse localization, with receptors present on dopamine and GABAergic terminals and possibly on some GABAergic interneurons and serotonin afferents in the striatum (Kulak et al., 2002a; Zoli et al., 2002; Chaptiaux et al., 2003; Quik et al, 2003, 2004; Bohr et al., 2005) (see section III.A.2; Fig. 4a). An almost complete dopaminergic lesion leads to only a 30 to 50% decline in striatal α4β2* nAChRs; this would suggest that 50 to 70% of the α4β2* receptors are present on dopaminergic terminals (Kulak et al., 2002a; Zoli et al., 2002; Chaptiaux et al., 2003; Quik et al., 2003). Studies using synaptosomal preparations, which primarily contain nerve terminals, suggest that stri-

### Table 2

<table>
<thead>
<tr>
<th>nAChR subtype</th>
<th>Present on Striatal Dopamine Terminals</th>
<th>Severity of Lesion</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Moderate</td>
<td>Severe</td>
</tr>
<tr>
<td>α6β2*</td>
<td>Yes</td>
<td>▼▼▼▼</td>
<td>▼▼▼▼</td>
</tr>
<tr>
<td>α6α4β2β3</td>
<td>Yes</td>
<td>▼▼▼▼</td>
<td>▼▼▼▼</td>
</tr>
<tr>
<td>α6β2β3</td>
<td>Yes</td>
<td>N.D.</td>
<td>▼▼▼▼</td>
</tr>
<tr>
<td>α3β2</td>
<td>Yes</td>
<td>▼▼▼▼</td>
<td>▼▼▼▼</td>
</tr>
<tr>
<td>α4β2</td>
<td>Yes</td>
<td>▼▼▼▼</td>
<td>▼▼▼▼</td>
</tr>
<tr>
<td>α4α5β2</td>
<td>Yes</td>
<td>▼▼▼▼</td>
<td>▼▼▼▼</td>
</tr>
<tr>
<td>α7</td>
<td>No</td>
<td>▼▼▼▼</td>
<td>▼▼▼▼</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▼▼▼▼</td>
<td>▼▼▼▼</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reference</th>
<th>Quik et al., 2001, 2005; Zoli et al., 2002</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate lesion</td>
<td>▼, decline; N.D., no change</td>
</tr>
</tbody>
</table>
atal presynaptic $\alpha_4\beta_2^*$ nACHRs consist of both the $\alpha_4\beta_2$ and the $\alpha_4\alpha_5\beta_2$ subtypes and are present on dopaminergic as well as other neurons (McClure-Begley et al., 2009; Grady et al., 2010b). Further evidence for this stems from studies showing that the $\alpha_5$ subunit declines by $\sim 90\%$ with nigrostriatal damage whereas the $\alpha_4$ subunit is decreased by only $\sim 50\%$ (Zoli et al., 2002). These data suggest that the greater proportion of $\alpha_4\alpha_5\beta_2$ nACHRs are present on dopaminergic terminals in the striatum, whereas the $\alpha_4\beta_2$ receptors are distributed on various neuronal types (Fig. 4a). Thus, with near complete denervation, there would be a major loss of the $\alpha_4\alpha_5\beta_2$ but only a partial decline in the $\alpha_4\beta_2$ receptor subtype.

Studies to evaluate effects of nigrostriatal damage on striatal $\alpha_7$ nACHRs are difficult because of their low expression levels in rat, monkey, and human striatum. However, where such studies have been done, $\alpha_7$ receptor expression seems not to change with lesioning (Quik et al., 2000a, 2003). These findings are consistent with the concept that $\alpha_7$ nACHRs are present on nondopaminergic terminals, including notably glutamatergic afferents, in the striatum (Fig. 4a) (Kaiser and Wonnacott, 2000).

Although there has been a general focus on the striatum, it is also important to consider the fate of nACHRs in the SN pars compacta with nigrostriatal damage. Work in this brain region is much more limited; however, studies in rats and monkeys have shown that nACHR binding is decreased with lesioning (Clarke and Pert, 1985; Quik et al., 2002, 2010). With respect to subtype selectivity, there is a more pronounced decline in $\alpha_6\beta_2^*$ compared with $\alpha_4\beta_2^*$ nACHR expression in the SN pars compacta with nigrostriatal damage (Quik et al., 2002, 2010). Because the decrease in $\alpha_6\beta_2^*$ nACHRs correlates with that in the dopamine transporter, these data are consistent with the localization of $\alpha_6\beta_2^*$ nACHR to somatodendritic sites on dopaminergic neurons (Klink et al., 2001). By contrast, $\alpha_4\beta_2^*$ nACHRs are present on dopaminergic neurons and GABAergic interneurons and afferents from the SN pars reticulata. Thus, residual somatodendritic nACHRs left after partial lesions or in the early stages of Parkinson's disease also offer credible therapeutic targets for nicotinic drugs, especially in view of their importance in driving burst firing and striatal dopamine release (see section III B.1). This identifies another area that merits further study.

To conclude, the nACHRs most affected by nigrostriatal damage are those present on dopaminergic neurons in the nigrostriatal pathway. The most pronounced losses are observed in the $\alpha_6\beta_2^*$ and $\alpha_4\alpha_5\beta_2$ subtypes; smaller declines are found in $\alpha_4\beta_2$ receptors, and there is no change in the $\alpha_7$ receptor subtype. These data, summarized in Fig. 6, suggest that drugs that target $\alpha_6\beta_2^*$ and $\alpha_4\beta_2^*$ nACHRs may prove most useful in ameliorating nACHR-mediated function with nigrostriatal damage.

V. Role for Nicotine and Nicotinic Acetylcholine Receptor Ligands in Parkinson's Disease

Parkinson's disease is frequently considered a disorder with a primary dysfunction of the nigrostriatal dopaminergic pathway. However, as discussed, the dopaminergic system is integrated with numerous other CNS systems, including the nicotinic cholinergic system (Calabresi and Di Filippo, 2008; Exley and Cragg, 2008; Barik and Wonnacott, 2009). The close functional interaction between the cholinergic and dopaminergic systems forms the basis for

![Fig. 6. Schematic diagram depicting the effects of partial and near-complete dopaminergic lesioning on expression of nACHR subtypes in striatum.](image-url)
the hypothesis that nAChR drugs may be useful for Parkinson's disease therapy. Accumulating evidence suggests that nicotine and nAChR ligands may influence Parkinson's disease motor symptoms via two distinct mechanisms: 1) they may protect against nigrostriatal damage to improve motor control over the long term. 2) In addition, nAChR ligands may directly stimulate the dopaminergic system to acutely ameliorate motor-related symptoms.

In the following sections, we describe the evidence that nAChR drugs may be valuable as a disease-modifying therapy for neuroprotection against nigrostriatal degeneration and may also be helpful for alleviating treatment-related side effects, specifically L-DOPA-induced dyskinesias.

VI. Smoking, Nicotine, and Neuroprotection against Nigrostriatal Damage

A. Epidemiological Studies and Smoking

Over a half-century of studies show overwhelmingly that smoking is inversely associated with Parkinson's disease (Morens et al., 1995; Gorell et al., 1999; Hernán et al., 2001; Allam et al., 2004; Alves et al., 2004; Ritz et al., 2007; Thacker et al., 2007; Elbaz and Moisan, 2008; Morozova et al., 2008; Chen et al., 2010; Ritz and Rhodes, 2010) and other body-related pathologic conditions (Tsuang et al., 2010). A prime question is whether this decreased incidence of Parkinson's disease in those with a history of smoking is due to the increased mortality risk associated with smoking. This appears not to be the case as data from several epidemiological studies, including a large prospective cohort, showed that mortality in patients with Parkinson's disease was not influenced by smoking status; that is, mortality was similar in nonsmoking and smoking patients with Parkinson's disease (Alves et al., 2004; Driver et al., 2008). The inverse correlation between smoking and Parkinson's disease is dose-dependent, with a decreased disease incidence with both increased smoking intensity (number of cigarettes smoked per day) and number of years of smoking (Morens et al., 1995; Gorell et al., 1999; Hernán et al., 2001; Allam et al., 2004; Alves et al., 2004; Ritz et al., 2007; Thacker et al., 2007; Elbaz and Moisan, 2008; Morozova et al., 2008; Chen et al., 2010; Ritz and Rhodes, 2010). The reduced Parkinson's disease incidence seems to be independent of sex and education, is more pronounced in current than in former smokers, and also occurs with other forms of tobacco, such as cigars, pipes, chewing tobacco, or snuff (O'Reilly et al., 2005; Ritz and Zoli, 2008; Benchérif, 2009). A frequently used rat model involves unilateral administration of 6-hydroxydopamine into the striatum, SN pars compacta, or medial forebrain bundle or hemisection of the nigrostriatal dopaminergic pathway (Figs. 1 and 6) (Cenci and Lundblad, 2007). These treatment protocols result in unilateral declines in striatal dopaminergic function, with contralateral deficits in motor activity. Bilateral models are not used because these are incompatible with animal survival (Cenci and Lundblad, 2007). In rats, nicotine pretreatment before lesioning reduces neuronal damage as assessed using markers of striatal dopaminergic integrity, such as dopamine and metabolite levels, tyrosine hydroxylase, the dopamine transporter, and the vesicular monoamine transporter. As expected, the degree of protection against nigrostriatal damage is dependent on lesion size, with optimal effectiveness against moderate lesioning. Nicotine dosing is also an important variable. Nicotine exhibits a U-shaped dose-response curve; that is, maximal protection is seen with intermediate nicotine dosing regimens (Costa et al., 2001; Ryan et al., 2001; Soto-Otero et al., 2002). Studies using MPTP-lesioned monkeys, a model that more closely mimics features of Parkinson's disease, also show that a 2-month nicotine pretreatment period protects against nigrostriatal damage (Quik et al., 2006a,b). As reviewed earlier, the ability of nicotine to protect against dopaminergic damage in parkinsonian mice has been inconsistent with positive results in some studies but not others (Quik et al., 2007b). A likely explanation for this variability in mice may relate to their rapid rate of nicotine metabolism ($t_{1/2} = 5–10$ min in mice compared with 60 min in rats and monkeys) (Matta et al., 2007).

Although nicotine is clearly protective against toxin-induced nigrostriatal damage in parkinsonian rats and monkeys, it should be noted that nicotine does not restore function if administered to parkinsonian animals when nigrostriatal damage is complete (Huang et al., 2009). A 2- to 3-week nicotine regimen given before nigrostriatal dam-
agage improved dopamine transporter levels in the striatum of lesioned rats compared with animals not receiving nicotine. However, there was no change in transporter levels when nicotine was administered to rats after lesioning and subsequently given nicotine for the same time interval (Huang et al., 2009). These observations suggest that nicotine's primary action is protection against ongoing degeneration rather than restoration of damaged neurons.

In addition to nicotine, smoking contains numerous other components, any of which may play a synergistic and/or additive role in protection against nigrostriatal damage. As mentioned earlier, this includes agents that modulate metabolic enzymes such as monoamine oxidase (Castagnoli and Murugesan, 2004). The rationale for this possibility stemmed from studies showing reduced levels of monoamine oxidase activity in the brains of smokers (Fowler et al., 1996a,b). In addition, other work showed that tobacco components that inhibit monoamine amine oxidase activity protected against nigrostriatal damage in mouse striatum (Castagnoli et al., 2001). These data provide support for the idea that monoamine oxidase inhibitors in tobacco may decrease enzymic activity in the brains of patients with Parkinson's disease, thereby reducing the synthesis of endogenous toxins that cause nigrostriatal damage in addition to prolonging the availability of dopamine. Nicotine and/or other agents in tobacco may also act by modifying brain expression of cytochrome P450 (P450). This possibility stemmed from work showing that enzymic activity is higher in smokers and is induced by nicotine in experimental animals. Enhanced P450 expression may contribute to neuroprotection by increasing the breakdown of toxic agents that damage the nigrostriatal dopaminergic system (Miksys and Tyndale, 2006).

In summary, epidemiological data show that smoking represents the largest, most consistent negative risk factor for Parkinson's disease. Experimental studies with parkinsonian animals demonstrate that nicotine significantly reduces nigrostriatal damage, with an average 30% protection in different animal models. These combined data support the hypothesis that nicotine treatment may yield a therapeutic strategy to reduce Parkinson's disease progression. Motor symptoms generally only arise in Parkinson's disease when nigral dopaminergic neurons are reduced by >50% and striatal dopamine by >70% (Olanow, 2004; Samii et al., 2004). Therefore, a 30% protection against nigrostriatal damage may allow for normal function for many years before Parkinson's disease symptoms arise. Although studies have been done to evaluate the symptomatic benefits of short-term nicotine administration, as detailed in section VIIA, nicotine's potential to protect against neuronal damage in Parkinson's disease is not known. A recent Michael J. Fox Foundation-funded international clinical trial vetting the potential of a nicotine skin patch to modify the progression of Parkinson's disease should provide some answers to this important question.

VII. Nicotine and Symptomatic Improvement

A. Patients with Parkinson's Disease

A number of reports and small clinical trials over the last 2 decades show that nicotine treatment reduces motor symptoms in patients with Parkinson's disease (Ishikawa and Miyatake, 1993; Fagerström et al., 1994; Kelton et al., 2000; Mitsuoka et al., 2002; Hanagasi et al., 2007). However, these are counterbalanced by an approximately equal number of studies that demonstrate no improvement in clinical features with either nicotine or a nicotinic agonist (Clemens et al., 1995; Vierregge et al., 2001; Lemay et al., 2004; Parkinson Study Group, 2006) or even a slight worsening of symptoms (Ebersbach et al., 1999). A comparison of the different studies was done with the intent of identifying factors that may account for the positive outcomes (Table 3). Careful analyses suggested that improvement did not correlate with nicotine formulation, dosage, or treatment paradigm. Instead, the most obvious success indicator seemed to relate to study design. Improvement was observed in studies with only a small number of pa-

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Improve Parkinsonism</th>
<th>Nicotine Formulation</th>
<th>No. of Patients</th>
<th>Treatment Regimen</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Open-label</td>
<td>Yes</td>
<td>Smoking/ nicotine gum</td>
<td>6</td>
<td>Chronic smoker</td>
<td>Ishikawa and Miyatake, 1993</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>Intravenous nicotine and patch</td>
<td>15</td>
<td>2 weeks</td>
<td>Kelton et al., 2000</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>Nicotine gum</td>
<td>8</td>
<td>N.D.</td>
<td>Mitsuoka et al., 2002</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>Smoking</td>
<td>1</td>
<td>1 day</td>
<td>Hanagasi et al., 2007</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>Nicotine patch</td>
<td>6</td>
<td>14 weeks</td>
<td>Villafane et al., 2007</td>
</tr>
<tr>
<td>Double-blinded</td>
<td>No</td>
<td>Nicotine patch</td>
<td>22</td>
<td>22 days</td>
<td>Lemay et al., 2004</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>Nicotine gum</td>
<td>48</td>
<td>3 days</td>
<td>Clemens et al., 1995</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>Nicotine patch</td>
<td>16</td>
<td>12 h</td>
<td>Ebersbach et al., 1999</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>SIB-1508Y</td>
<td>32</td>
<td>1 week</td>
<td>Vierregge et al., 2001</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>Nicotine gum and patch</td>
<td>77</td>
<td>2 weeks</td>
<td>Parkinson Study Group, 2006</td>
</tr>
</tbody>
</table>

TABLE 3

Clinical improvement of Parkinsonism with nicotine treatment correlates best with study design

Parkinsonism was assessed by measurement of a variety of different outcomes, including testing of fine motor skills, tremor, rigidity, bradykinesia, posture, hand and finger dexterity, or by using the following rating scales: the Unified Parkinson's Disease Rating Scale, Hoehn and Yahr, Columbia University, and Schwab-England.

<table>
<thead>
<tr>
<th>Study Design</th>
<th>Improve Parkinsonism</th>
<th>Nicotine Formulation</th>
<th>No. of Patients</th>
<th>Treatment Regimen</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Open-label</td>
<td>Yes</td>
<td>Smoking/ nicotine gum</td>
<td>6</td>
<td>Chronic smoker</td>
<td>Ishikawa and Miyatake, 1993</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>Intravenous nicotine and patch</td>
<td>15</td>
<td>2 weeks</td>
<td>Kelton et al., 2000</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>Nicotine gum</td>
<td>8</td>
<td>N.D.</td>
<td>Mitsuoka et al., 2002</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>Smoking</td>
<td>1</td>
<td>1 day</td>
<td>Hanagasi et al., 2007</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>Nicotine patch</td>
<td>6</td>
<td>14 weeks</td>
<td>Villafane et al., 2007</td>
</tr>
<tr>
<td>Double-blinded</td>
<td>No</td>
<td>Nicotine patch</td>
<td>22</td>
<td>22 days</td>
<td>Lemay et al., 2004</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>Nicotine gum</td>
<td>48</td>
<td>3 days</td>
<td>Clemens et al., 1995</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>Nicotine patch</td>
<td>16</td>
<td>12 h</td>
<td>Ebersbach et al., 1999</td>
</tr>
<tr>
<td></td>
<td>No</td>
<td>SIB-1508Y</td>
<td>32</td>
<td>1 week</td>
<td>Vierregge et al., 2001</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>Nicotine gum and patch</td>
<td>77</td>
<td>2 weeks</td>
<td>Parkinson Study Group, 2006</td>
</tr>
</tbody>
</table>

N.D., not determined; N.A., not available.
tients (1–15 patients), with no effect of nicotine on Parkinson's disease symptoms in the larger study groups (16–77 patients). In addition, improvement seems to correlate with an open label but not placebo-controlled protocol. Although initially unexpected, this latter outcome is consistent with work that demonstrates significant improvements in Parkinson disease symptoms with placebo treatments, with a 9 to 59% placebo effect across different trials (de la Fuente-Fernández and Stoessl, 2002; Goetz et al., 2008). A large, recent analysis involving 858 patients with Parkinson's disease on placebo demonstrated an overall placebo response rate of 16%, with a range of 0 to 55% (Goetz et al., 2008). These finding highlight the importance of including a placebo group in drug and other experimental trials.

B. Parkinsonian Animal Models

The clinical data demonstrating inconsistent effects of nicotine on Parkinson's disease motor symptoms are in agreement with results in parkinsonian animal models (Table 4). Work with unilateral 6-hydroxydopamine-lesioned rats or mice show that neither short- nor long-term nicotine treatment modified parkinsonism either with or without L-DOPA treatment (Bordia et al., 2008, 2010; Huang et al., 2011). In these experiments, the effect of nicotine on motor function was tested only after toxin-induced nigrostriatal damage was complete. In another approach, because modifications in L-DOPA treatment generally compromise the control of Parkinson's disease symptoms, whereas dopamine agonists fail to be as effective as L-DOPA and are associated with their own set of side effects. Amantadine, a drug with multiple CNS actions, including inhibition of NMDA glutamate receptors, is currently the only drug that is used clinically for the treatment for L-DOPA-induced dyskinesias, although its efficacy is limited. Continuous delivery therapies are under consideration to minimize the fluctuations in dopamine levels that may contribute to the development of dyskinesias. These include subcutaneous or intravenous dopamine agonist therapies, transdermal patches with dopamine agonists, or intraduodenal L-DOPA infusion. Other pharmacological treatments include concurrent L-DOPA treatment with catechol-O-methyl transferase and monoamine oxidase inhibitors to prolong L-DOPA effectiveness (Jankovic and Stacy, 2007; Fahn, 2008; Lang, 2009; Poewe, 2009; Schapira et al., 2009; Pezzoli and Zini, 2010). These abnormal involuntary movements of the head, trunk, and/or extremities interfere with functions of daily living and may become very debilitating. They are relatively common with approximately a 30% incidence after 2 years of L-DOPA treatment, 40% by 5 years, and 90% by 10 years (Ahlskog and Muenter, 2001). A variety of strategies have been proposed to minimize their onset, including a delay in the initiation of L-DOPA therapy, reduction in L-DOPA dose and/or treatment with dopamine agonists (Fahn, 2008; Lang, 2009; Poewe, 2009; Schapira et al., 2009; Pezzoli and Zini, 2010). However, there are drawbacks to these approaches, because modifications in L-DOPA treatment generally compromise the control of Parkinson's disease symptoms, whereas dopamine agonists fail to be as effective as L-DOPA and are associated with their own set of side effects.

TABLE 4
Variable effects of nicotine on parkinsonism in animal models with nigrostriatal damage

<table>
<thead>
<tr>
<th>Animal Model &amp; Change in Parkinsonism</th>
<th>Drug</th>
<th>Study Duration</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>6-OHDA-lesioned rat</td>
<td>None</td>
<td></td>
<td>Bordia et al., 2008</td>
</tr>
<tr>
<td>Improvement</td>
<td>Nicotine</td>
<td>Weeks</td>
<td>Meshul et al., 2002</td>
</tr>
<tr>
<td>6-OHDA-lesioned mouse</td>
<td>None</td>
<td></td>
<td>Huang et al., 2011</td>
</tr>
<tr>
<td>MPTP-lesioned monkey</td>
<td>Nicotine</td>
<td>Weeks</td>
<td>Quik et al., 2006b</td>
</tr>
<tr>
<td>None</td>
<td>Nicotine</td>
<td>Acute dose</td>
<td>Domino et al., 1999</td>
</tr>
<tr>
<td>Improvement</td>
<td>Nicotine</td>
<td>Acute dose</td>
<td>Schneider et al., 1998</td>
</tr>
<tr>
<td>Synergistic with L-DOPA</td>
<td>SIB-1508Y</td>
<td>Acute dose</td>
<td>Schneider et al., 1998</td>
</tr>
</tbody>
</table>

6-OHDA, 6-hydroxydopamine.

VIII. Nicotine and L-DOPA-Induced Dyskinesias

A. L-DOPA Treatment for Parkinson's Disease Induces Dyskinesias

As stated earlier, the most prominent problem in Parkinson's disease is the motor deficits, which can effectively be treated with dopamine replacement therapies. The "gold standard" treatment is with the dopamine precursor L-DOPA, which greatly improves quality of life particularly in the early stages of the disease. However, long-term L-DOPA use results in the development of side effects such as dyskinesias (Fahn, 2008; Lang, 2009; Poewe, 2009; Schapira et al., 2009; Pezzoli and Zini, 2010). These abnormal involuntary movements of the head, trunk, and/or extremities interfere with functions of daily living and may become very debilitating. They are relatively common with approximately a 30% incidence after 2 years of L-DOPA treatment, 40% by 5 years, and 90% by 10 years (Ahlskog and Muenter, 2001). A variety of strategies have been proposed to minimize their onset, including a delay in the initiation of L-DOPA therapy, reduction in L-DOPA dose and/or treatment with dopamine agonists (Fahn, 2008; Lang, 2009; Poewe, 2009; Schapira et al., 2009; Pezzoli and Zini, 2010). However, there are drawbacks to these approaches, because modifications in L-DOPA treatment generally compromise the control of Parkinson's disease symptoms, whereas dopamine agonists fail to be as effective as L-DOPA and are associated with their own set of side effects. Amantadine, a drug with multiple CNS actions, including inhibition of NMDA glutamate receptors, is currently the only drug that is used clinically for the treatment for L-DOPA-induced dyskinesias, although its efficacy is limited. Continuous delivery therapies are under consideration to minimize the fluctuations in dopamine levels that may contribute to the development of dyskinesias. These include subcutaneous or intravenous dopamine agonist therapies, transdermal patches with dopamine agonists, or intraduodenal L-DOPA infusion. Other pharmacological treatments include concurrent L-DOPA treatment with catechol-O-methyl transferase and monoamine oxidase inhibitors to prolong L-DOPA effectiveness (Jankovic and Stacy, 2007; Fahn, 2008; Lang, 2009; Poewe, 2009; Schapira et al., 2009; Obeso et al., 2010). A surgical strategy that holds great promise in certain subsets of patients is deep-brain stimulation; however, its invasive nature is a limiting factor (Fahn, 2008; Benabid et al., 2009). Overall, the control of L-DOPA-induced dyskinesias is fairly limited. There is therefore a great unmet need to identify novel therapies.
Knowledge of the cellular and molecular mechanisms responsible for the occurrence of L-DOPA-induced dyskinesias would greatly facilitate in the development of targeted treatments. Indeed, this is an area under investigation in numerous laboratories. L-DOPA seems to mediate its initial effects via a dopamine receptor D1-mediated interaction. A current hypothesis is that dyskinesias arise because of an inability to turn down supersensitive signaling responses downstream of dopamine D1 receptors that arose in response to nigrostriatal dopaminergic denervation. DARPP-32 is one of the targets modified in L-DOPA-induced dyskinesias in rodents, with increased phosphorylation of its activating Thr34 site and several downstream targets including extracellular signal-regulated kinase and cFos (Picconi et al., 2003; Santini et al., 2007). The sustained activation of intracellular signaling pathways induced by multiple L-DOPA dosing leads to aberrant CNS activity that is behaviorally expressed as abnormal involuntary movements (Cenci and Konradi, 2010). This is compatible with the dependence of the molecular changes in L-DOPA-induced dyskinesia on supersensitive D1 receptor activation. This model implicates predominantly the “direct” output pathway that disinhibits the thalamus to promote motor commands (Fig. 3).

In addition to the dopaminergic system, evidence also suggests a prominent involvement of the serotonergic system in the occurrence of L-DOPA-induced dyskinesias. This idea is based on work showing that L-DOPA-induced dyskinesias are reduced with serotonergic denervation of the raphe nuclei or by treatment with selective serotonergic antagonists (Carta et al., 2007, 2008b; Eskow et al., 2007, 2009; Muñoz et al., 2008). Serotonergic inputs from the raphe to SN, and to a lesser extent to the striatum, the globus pallidus and the subthalamus are most likely involved (Di Matteo et al., 2008). Indeed, increased sprouting of serotonin terminals in the striatum is associated with the presence of L-DOPA-induced dyskinesias (Rylander et al., 2010). These data suggest that treatments that diminish serotonergic tone may be of clinical benefit in the management of L-DOPA-induced dyskinesias in patients with Parkinson’s disease. The possibility of nicotinic modulation of this serotonergic system remains to be investigated.

In fact, research is in progress in numerous laboratories to investigate the antidyskinetic potential of drugs directed to various molecular targets linked to the nigrostriatal system, including the glutamatergic, GABAergic, adenosine, cannabinoid, noradrenergic, and other systems (Carta et al., 2008a; Fox et al., 2008; Jenner, 2008a,b; Cao et al., 2010; Lebel et al., 2010; Morin et al., 2010). Work is also being done to investigate the antidyskinetic potential of nicotine and nAChR-directed ligands in view of the extensive nicotinic cholinergic innervation in the nigrostriatal system (Quik et al., 2009).

### B. Nicotine Decreases L-DOPA-Induced Dyskinesias in Parkinsonian Animal Models

Studies in several parkinsonian animal models show that nicotine treatment results in significant declines in L-DOPA-induced dyskinesias (Quik et al., 2007a; Bordia et al., 2008, 2010; Huang et al., 2011). Long-term nicotine dosing via several different modes of administration, including drinking water, minipump, and injection, decreased L-DOPA-induced dyskinetic movements in unilateral 6-hydroxydopamine-lesioned mice and rats and also in MPTP-lesioned monkeys, a model that bears many resemblances to Parkinson’s disease. Tolerance did not seem to develop, with the effect of nicotine persisting with prolonged treatment time (months) (Quik et al., 2007a; Bordia et al., 2008, 2010; Huang et al., 2011).

An important question that arises is the subtype and location of nAChRs that underlie nicotine’s ability to reduce L-DOPA-induced dyskinesias, because this may allow for the development of selective pharmacotherapies with minimal side effects. As summarized in the schematic in Fig. 6, the most relevant current targets seem to be the α6β2* and α4β2* nAChRs. We therefore tested the effect of agonists directed to these subtypes for their antidyskinetic potential in unilateral 6-hydroxydopamine-lesioned rats (Huang et al., 2011). Varenicline, an agonist that interacts with multiple nAChR subtypes (Mihalak et al., 2006; Rellera et al., 2007b), reduced L-DOPA-induced dyskinetic-like movements by 50% in parkinsonian rats. A similar decline was obtained with 5-iodo-A-85380, a nAChR agonist that interacts preferentially with α4β2* and α6β2* nAChRs (see section III.A.1). These latter two nAChR populations may thus be involved in the antidyskinetic effect. The effectiveness of these novel nAChR agonists, and also of nicotine, seemed dependent on the degree of nigrostriatal damage, with reductions in dyskinesias with moderate (~30%) but not near-complete (~99%) nigrostriatal lesions (Huang et al., 2011). None of the drugs reduced the antiparkinsonian action of L-DOPA, suggesting that the mechanisms by which nicotine modulates L-DOPA-induced dyskinesias are distinct from those involved in motor functions linked to parkinsonism.

In summary, nicotine and CNS agonists targeting α4β2* and α6β2* nAChR subtypes reduced L-DOPA-induced dyskinesias in a rodent model, the magnitude of the decline depending on the integrity of the dopaminergic system. These data suggest that α4β2* and α6β2* nAChR agonists may be useful for the treatment of L-DOPA-induced dyskinesias in Parkinson’s disease.

### IX. Conclusion and Future Directions

There is a consensus among epidemiologists that smoking is associated with a reduced incidence of Parkinson’s disease. These observations led to the hypothesis that the nicotine in tobacco may play a role in protection against nigrostriatal damage because nicotine is well known to interact with the dopaminergic system. This idea was sub-
stained by studies showing that nicotine treatment protected against neurotoxin-induced nigrostriatal damage in both rodent and nonhuman primate parkinsonian animal models. Converging evidence thus supports a clinical trial to determine whether nicotine reduces Parkinson’s disease progression.

Studies have also been done to investigate short-term effects of nicotine on Parkinson’s disease motor symptoms because nicotine is well known to modulate dopaminergic function in short-term studies. The results of this work are less clear with improvement in motor deficits in approximately half of the clinical trials and only in some studies involving parkinsonian animal models. These conflicting results may suggest that nicotine is ineffective or that it may possibly attenuates symptoms only under specified experimental conditions that remain to be identified. Further work is necessary to resolve this controversy.

More recent developments indicate that nicotine administration may be useful as an adjunct therapy to minimize L-DOPA-induced dyskinesias, a troubling side effect of L-DOPA therapy. Evidence for this stems from animal studies showing that nicotine reduces L-DOPA-induced dyskinesias in several parkinsonian animal models including rats, mice, and monkeys. These experimental observations suggest that a clinical trial testing the effect of nicotine may be warranted. Several nicotine formulations are currently available as smoking cessation aids, including the nicotine patch, gum, lozenge, nasal spray, and nasal inhalant. One or more of these applications may have potential for reducing L-DOPA-induced dyskinesias in Parkinson’s disease. The beneficial effects also seen with varenicline, a synthetic drug licensed for use in smoking cessation, against L-DOPA-induced dyskinesias in animal studies encourages the view that there is a therapeutic niche for new nicotinic ligands.

An outstanding gap at the present time is whether nicotine exerts its beneficial effects in Parkinson’s disease by acting at select nAChR subtypes and whether the same subtypes mediate the neuroprotective and the antidyssynaptic effects of nicotine. This knowledge is important as it may lead to directed therapies with optimal therapeutic benefits and minimal side effects. Initial studies suggest that drugs directed to α4β2* and α6β2* nAChR populations present on nigrostriatal dopaminergic terminal neurons, and notably on their afferents projecting to the striatum, may be most relevant both for symptomatic therapy and long-term protection against nigrostriatal damage. Further studies to identify the most relevant nAChR subtypes, and their signaling pathways may reveal novel drug targets to combat Parkinson’s disease.

Another gap in current knowledge relates to the most effective nAChR drug formulation for Parkinson’s disease management. nAChR agonists are well known to initiate a rapid receptor desensitization with a consequent functional blockade. The question that arises is whether nAChR agonists exert their beneficial effects via receptor activation, or by blocking receptor mediated activity, in which case antagonists may be more useful from a clinical standpoint. Alternatively, partial nAChR agonists (such as varenicline) may be more effective therapeutically. Continued research is required to address these possibilities.

Although not a focus of the current review, nonmotor symptoms are increasingly recognized as a significant problem in patients with Parkinson’s disease (Hawkes, 2008; O’Sullivan et al., 2008; Schapira, 2009; Obeso et al., 2010). These include olfactory dysfunction, sleep disorders, cognitive declines, depression, and pain. To our knowledge, studies have not yet been done to evaluate whether nicotine may relieve such symptoms in Parkinsonian animal models or in patients with Parkinson’s disease. However, nAChR drugs have been reported to modulate neuronal circuits involved in some of these deficits to facilitate cognitive performance, reduce pain, and alleviate depression (Bacher et al., 2009; Buckingham et al., 2009; McIntosh et al., 2009; Poorthuis et al., 2009; Sarter et al., 2009; Changeux, 2010a; Mineur and Picciotto, 2010; Philip et al., 2010). Thus, the use of nAChR drugs may not only protect against nigrostriatal damage and reduce L-DOPA-induced dyskinesias but also prove beneficial against nonmotor symptoms associated with Parkinson’s disease. Future work is necessary to address this gap.

Acknowledgments
This work was supported by National Institutes of Health National Institute of Neurological Disorders and Stroke [Grants NS42091, NS59910, NS65851]; the Michael J. Fox Foundation; the California Tobacco Related Disease Research Program [Grant 17RT-0119] (to M.Q.); and the Parkinson’s Disease Society (to S.W.). We thank Sharon Grady (University of Colorado, Boulder, CO), and Stephanie Cragg (University of Oxford, Oxford, UK), for helpful comments concerning the manuscript.

Authorship Contributions
Wrote or contributed to the writing of the manuscript: Quik and Wonnacott.

References


Obeso JA, Olanow CW, and Nutt JG (2000) Levodopa motor complications in Par-

Nishino N, Kitamura N, Hashimoto T, and Tanaka C (1993) Transmembrane sig-

O'Reilly EJ, McCullough ML, Chao A, Henley SJ, Calle EE, Thun MJ, and Ascherio A (2005) Smokeless tobacco use and the risk of Parkinson’s disease. J Pharmaco-


Parkinson’s disease.


Quik M, Vailati S, Bordia T, Kulak JM, Fan H, McIntosh JM, Clementi F, and Gotti C (2005) Subunit composition of nicotinic receptors in monkey striatum: effect of treatments with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine or L-DOPA. J Pharmacol Exp Ther 314:45–50.


Soderman AR, Mikkelsen JD, West MJ, Christensen DZ, and Jensen MS (2011) Activation of nicotinic alpha7 acetylcholine receptor enhances long term potentiation in wild type mice but not in APFvswie FS1129 mice. Neuropharmacology 57:325–332.


